



National  
Comprehensive  
Cancer  
Network®

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**

# **Chronic Myeloid Leukemia**

Version 1.2018 — July 26, 2017

**NCCN.org**

**Continue**



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 1.2018 Panel Members

## Chronic Myeloid Leukemia

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

**Jerald P. Radich, MD/Chair ξ**  
Fred Hutchinson Cancer Research  
Center/Seattle Cancer Care Alliance

**Michael Deininger, MD, PhD/Vice-Chair ‡ ξ**  
Huntsman Cancer Institute  
at the University of Utah

**Camille N. Abboud, MD ‡ ξ ρ**  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

**Jessica K. Altman, MD ‡**  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

**Ellin Berman, MD ‡ † ρ**  
Memorial Sloan Kettering Cancer Center

**Ravi Bhatia, MD ‡**  
University of Alabama at Birmingham  
Comprehensive Cancer Center

**Bhavana Bhatnagar, DO ‡**  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

**Peter Curtin, MD ‡ ξ**  
UC San Diego Moores Cancer Center

**Daniel J. DeAngelo, MD, PhD ‡ †**  
Dana-Farber/Brigham and Women's  
Cancer Center

**Jason Gotlib, MD, MS ‡ †**  
Stanford Cancer Institute

**Gabriela Hobbs, MD ‡ †**  
Massachusetts General Hospital Cancer Center

**Madan Jagasia, MD ‡ ξ**  
Vanderbilt-Ingram Cancer Center

**Hagop M. Kantarjian, MD ‡ † ρ**  
The University of Texas  
MD Anderson Cancer Center

**Lori Maness, MD ‡**  
Fred and Pamela Buffett Cancer Center

**Leland Metheny, MD ‡ ξ**  
Case Comprehensive Cancer Center  
University Hospitals Seidman Cancer Center  
and Cleveland Clinic Taussig Cancer Institute

**Joseph O. Moore, MD †**  
Duke Cancer Institute

**Arnel Pallera, MD ‡ †**  
St. Jude Children's Research Hospital  
The University of Tennessee Health Science  
Center

**Philip Pancari, MD ‡**  
Fox Chase Cancer Center

**Michal G. Rose, MD †**  
Yale Cancer Center/Smilow Cancer Hospital

**Neil P. Shah, MD, PhD ‡**  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**B. Douglas Smith, MD † ρ**  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**David S. Snyder, MD ‡ ξ**  
City of Hope Comprehensive  
Cancer Center

**Kendra L. Sweet, MD, MS ‡ † ρ**  
Moffitt Cancer Center

**Moshe Talpaz, MD †**  
University of Michigan  
Comprehensive Cancer Center

**James Thompson, MD ‡**  
Roswell Park Cancer Institute

**Raoul Tibes, MD, PhD ‡ † ρ**  
Mayo Clinic Cancer Center

**David T. Yang, MD ≠**  
University of Wisconsin  
Carbone Cancer Center

### NCCN

**Kristina Gregory, RN, MSN, OCN**  
**Hema Sundar, PhD**

‡ Hematology/Hematology oncology  
† Medical oncology  
ρ Internal medicine  
≠ Pathology  
ξ Bone marrow transplantation  
Δ Cancer genetics  
\* Discussion Section Writing Committee

**Continue**

[NCCN Guidelines Panel Disclosures](#)



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 1.2018 Table of Contents

## Chronic Myeloid Leukemia

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

- [NCCN Chronic Myeloid Leukemia Panel Members](#)
- [Summary of Guidelines Updates \(Updates\)](#)
- [Workup \(CML-1\)](#)
- [Chronic Phase CML: Primary Treatment \(CML-2\)](#)
- [Response Milestones, Clinical Considerations, and Treatment Options \(CML-3\)](#)
- [Advanced Phase CML: Primary Treatment \(CML-4\)](#)
- [Treatment Options Based on BCR-ABL1 Mutation Profile \(CML-5\)](#)
- [Hematopoietic Cell Transplantation \(CML-6\)](#)
- [Risk Calculation Table \(CML-A\)](#)
- [Definitions of Accelerated Phase and Blast Phase \(CML-B\)](#)
- [Monitoring Response to TKI Therapy and Mutational Analysis \(CML-C\)](#)
- [Criteria for Hematologic, Cytogenetic, and Molecular Response and Relapse \(CML-D\)](#)
- [Criteria for Discontinuation of TKI Therapy \(CML-E\)](#)
- [Management of Toxicities \(CML-F\)](#)
- [Management of Bosutinib Toxicity \(CML-F 1 of 6\)](#)
- [Management of Dasatinib Toxicity \(CML-F 2 of 6\)](#)
- [Management of Imatinib Toxicity \(CML-F 3 of 6\)](#)
- [Management of Nilotinib Toxicity \(CML-F 4 of 6\)](#)
- [Management of Omacetaxine Toxicity \(CML-F 5 of 6\)](#)
- [Management of Ponatinib Toxicity \(CML-F 6 of 6\)](#)

**Clinical Trials:** NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical\\_trials/physician.html](#).

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.



# NCCN Guidelines Version 1.2018 Updates

## Chronic Myeloid Leukemia

Updates in Version 1.2018 of the NCCN Guidelines for Chronic Myeloid Leukemia from Version 2.2017 include:

### CML-1

- **Workup**
  - ▶ **Bullet 2: "Platelets" removed**
  - ▶ **Bullet 4 modified and combined with sub-bullet: "Bone marrow evaluation aspirate and biopsy for morphologic review and cytogenetic evaluation"**
  - ▶ **Bullet 5 and sub-bullet removed: "Cytogenetics > FISH (blood, if bone marrow not available)"**
  - ▶ **Bullet 6 removed: "Molecular"**
  - ▶ **Sub-bullet to bullet 6 is the new bullet 6: "Quantitative RT-PCR (QPCR) using International Scale (IS) for *BCR-ABL1* (blood)"**
  - ▶ **Bullet 7 removed: "ECG for prolonged QTc"**
  - ▶ **Bullet 10 modified with the specification of test for the hepatitis panel: "hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [HBsAb], hepatitis B core antibody [anti-HBc], IgM anti-HBc, IgG anti-HBc"**
- **Footnote a modified: "Bone marrow evaluation should be done for the initial workup, not only to provide morphologic review, but and also to detect other chromosomal abnormalities in addition to *Ph* chromosome that are not detectable on peripheral blood FISH. FISH can be used if cytogenetic evaluation is not possible."**

### CML-2

- **Treatment Considerations moved to second column.**
- **Primary Treatment; Intermediate- or high-risk score**
  - ▶ **Nilotinib and Dasatinib: preferred designation removed.**
- **Footnote d modified: "Preliminary Long-term follow-up data suggest that patients with an intermediate- or high-risk Sokal or Hasford score may preferentially benefit from dasatinib or nilotinib. See Discussion for additional information."**

### CML-3

- ***BCR-ABL1* (IS) category changed from 1%–10% to >1%–10% and 0.1%–<1% to 0.1%–1%. (also applies to CML-D)**

### CML-4

- **Treatment Considerations moved to second column.**
  - ▶ **Bullet 1 modified: "Evaluate for Role of allogeneic HCT should be discussed based on response:"**

### CML-6

- **Footnote p moved into the algorithm: "Consider TKI therapy for at least one year in patients with prior accelerated or blast phase CML"**
- **Previous footnote p (now footnote n) replaced with "See Discussion."**

### CML-B

- **Modified Criteria Used at MD Anderson Cancer Center**
  - ▶ **Bullet 5 modified: "Clonal evolution Additional clonal cytogenetic abnormalities in *Ph*+ cells"**
- **World Health Organization (WHO) Criteria removed.**

### CML-D 2 OF 2

- **Cytogenetic Assessment of Response to TKI Therapy removed.**

### CML-D

- **Relapse, bullet 2 clarified: "1-log increase in *BCR-ABL1* transcript levels with loss of MMR should prompt bone marrow evaluation for loss of CCyR but is not itself defined as relapse (eg, hematologic or cytogenetic relapse)"**
- **Footnote 4 added: "CCyR typically correlates with *BCR-ABL1*(IS) 0.1%–1%."**

### CML-E

- **Last bullet, sub-bullet 3 added: "Failure to regain MMR after three months following treatment reinitiation."**




# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### WORKUP

- H&P, including spleen size by palpation (cm below costal margin)
- CBC with differential
- Chemistry profile
- Bone marrow<sup>a</sup> aspirate and biopsy for morphologic and cytogenetic evaluation
- Quantitative RT-PCR (QPCR) using International Scale (IS) for *BCR-ABL1* (blood)
- Hepatitis panel (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [HBsAb], hepatitis B core antibody [anti-HBc], IgM anti-HBc, IgG anti-HBc)



<sup>a</sup>Bone marrow evaluation should be done for the initial workup, to provide morphologic review, and also to detect other chromosomal abnormalities in addition to Ph chromosome. FISH can be used if cytogenetic evaluation is not possible.

<sup>b</sup>[See Definitions of Accelerated Phase and Blast Phase \(CML-B\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### CLINICAL PRESENTATION

### PRIMARY TREATMENT



<sup>c</sup>See [Monitoring Response to TKI Therapy and Mutational Analysis \(CML-C\)](#).

<sup>d</sup>Long-term follow-up data suggest that patients with an intermediate- or high-risk Sokal or Hasford score may preferentially benefit from dasatinib or nilotinib. See [Discussion](#) for additional information.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### RESPONSE MILESTONES<sup>c,e</sup>

<i>BCR-ABL1</i> (IS)	3 months	6 months	12 months	>12 months
>10% <sup>f</sup>	YELLOW	RED		
>1%–10%	GREEN		YELLOW	RED
0.1%–1%	GREEN			YELLOW
<0.1%	GREEN			

### CLINICAL CONSIDERATIONS

### SECOND-LINE AND SUBSEQUENT TREATMENT OPTIONS

RED	<ul style="list-style-type: none"> <li>Evaluate patient compliance and drug interactions</li> <li>Mutational analysis</li> </ul>	Switch to alternate TKI ( <a href="#">CML-5</a> ) and Evaluate for HCT ( <a href="#">CML-6</a> )
YELLOW	<ul style="list-style-type: none"> <li>Evaluate patient compliance and drug interactions</li> <li>Mutational analysis</li> </ul>	Switch to alternate TKI ( <a href="#">CML-5</a> ) or Continue same TKI ( <a href="#">CML-F</a> ) <sup>g</sup> or Dose escalation of imatinib (to a max of 800 mg) and Evaluate for HCT ( <a href="#">CML-6</a> )
GREEN	<ul style="list-style-type: none"> <li>Monitor response (<a href="#">CML-F</a>) and side effects</li> </ul>	Continue same TKI ( <a href="#">CML-F</a> ) <sup>h</sup>

<sup>c</sup>See [Monitoring Response to TKI Therapy and Mutational Analysis \(CML-C\)](#).

<sup>e</sup>See [Criteria for Hematologic, Cytogenetic, and Molecular Response and Relapse \(CML-D\)](#).

<sup>f</sup>Patients with *BCR-ABL1* only slightly >10% at 3 months and/or with a steep decline from baseline, may achieve <10% at 6 months and have generally favorable outcomes. Therefore, it is important to interpret the value at 3 months in this context, before making drastic changes to the treatment strategy.

<sup>g</sup>Achievement of response milestones must be interpreted within the clinical context. Patients with more than 50% reduction compared to baseline or minimally above the 10% cutoff can continue the same dose of dasatinib or nilotinib for another 3 months.

<sup>h</sup>Discontinuation of TKI with careful monitoring is feasible in selected patients. See [Discontinuation of TKI Therapy \(CML-E\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### CLINICAL PRESENTATION

### TREATMENT



<sup>b</sup>[See Definitions of Accelerated Phase and Blast Phase \(CML-B\).](#)

<sup>i</sup>Omacetaxine is a treatment option for patients with disease progression to accelerated phase CML. Omacetaxine is not a treatment option for patients who present with accelerated phase CML.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### TREATMENT OPTIONS BASED ON BCR-ABL1 MUTATION PROFILE

Mutation	Treatment Recommendation <sup>j</sup>
Y253H, E255K/V, or F359V/C/I	<a href="#">Dasatinib</a>
F317L/V/I/C, T315A, or V299L	<a href="#">Nilotinib</a>
E255K/V, F317L/V/I/C, F359V/C/I, T315A, or Y253H	<a href="#">Bosutinib</a>
T315I	<a href="#">Ponatinib</a> , <sup>k</sup> <a href="#">Omacetaxine</a> , <sup>l</sup> allogeneic HCT ( <a href="#">CML-6</a> ), or clinical trial

<sup>j</sup>Patients with disease that is resistant to primary treatment with imatinib should be treated with nilotinib, dasatinib, or bosutinib in the second-line setting. Patients with disease that is resistant to primary treatment with nilotinib or dasatinib could be treated with an alternate TKI (other than imatinib) in the second-line setting.

<sup>k</sup>Ponatinib is a treatment option for patients with a T315I mutation or for patients for whom no other TKI is indicated


<sup>l</sup>Omacetaxine is a treatment option for patients with disease that is resistant and/or intolerant to 2 or more TKIs.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



### FOLLOW-UP THERAPY



<sup>e</sup>See [Criteria for Hematologic, Cytogenetic, and Molecular Response and Relapse \(CML-D\)](#).

<sup>m</sup>Indications for allogeneic HCT: Advanced phase CML at presentation or disease progression to blast phase. Outcomes of allogeneic HCT are dependent on age and comorbidities, donor type, and transplant center.

<sup>n</sup>See [Discussion](#).

<sup>o</sup>In patients who have disease that has failed prior TKI therapy, see [CML-5](#) for the selection of post-HCT TKI.

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### RISK CALCULATION TABLE

Study	Calculation	Risk Definition by Calculation	
Sokal et al, 1984 <sup>1</sup>	$\text{Exp } 0.0116 \times (\text{age in years} - 43.4) + (\text{spleen} - 7.51) + 0.188 \times [(\text{platelet count} \div 700)^2 - 0.563] + 0.0887 \times (\text{blast cells} - 2.10)$	Low	<0.8
		Intermediate	0.8 - 1.2
		High	>1.2
Hasford et al, 1998 <sup>2</sup>	<b>0.666 when age <math>\geq</math> 50 years + (0.042 x spleen) + 1.0956 when platelet count <math>&gt;</math> 1500 x 10<sup>9</sup>/L + (0.0584 x blast cells) + 0.20399 when basophils <math>&gt;</math> 3% + (0.0413 x eosinophils) x 100</b>	Low	$\leq$ 780
		Intermediate	781 - 1480
		High	>1480

Calculation of relative risk found at <http://www.icsg.unibo.it/rccalc.asp>. Age is in years. Spleen is in centimeter below the costal margin (maximum distance). Blast cells, eosinophils, and basophils are in percents of peripheral blood differential. All factors must be collected prior to any treatment.

Reprinted with permission. © 2009 American Society of Clinical Oncology. All Rights Reserved. Baccarani M, Cortes J, Pane F, Niederwieser D, et al. European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-6051.

<sup>1</sup>Sokal J, Cox E, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6584184>.

<sup>2</sup>Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9625174>.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### DEFINITION OF ACCELERATED PHASE<sup>1,2</sup>

#### Modified Criteria Used at MD Anderson Cancer Center<sup>3,4</sup> (most commonly used in clinical trials)

- Peripheral blood blasts  $\geq 15\%$  and  $< 30\%$
- Peripheral blood blasts and promyelocytes combined  $\geq 30\%$
- Peripheral blood basophils  $\geq 20\%$
- Platelet count  $\leq 100 \times 10^9/L$  unrelated to therapy
- Additional clonal cytogenetic abnormalities in Ph+ cells

### DEFINITIONS OF BLAST PHASE<sup>1</sup>

#### World Health Organization (WHO) Criteria<sup>5</sup>

- Blasts  $\geq 20\%$  of peripheral white blood cells or of nucleated bone marrow cells
- Extramedullary blast proliferation
- Large foci or clusters of blasts in the bone marrow biopsy

#### International Bone Marrow Transplant Registry<sup>6</sup>

- $\geq 30\%$  blasts in the blood, marrow, or both
- Extramedullary infiltrates of leukemic cells

<sup>1</sup>The table refers to myeloblasts. Any increase in lymphoblasts is concerning for (nascent) blast phase.

<sup>2</sup>Sokal criteria (Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61) and IBMTR criteria (Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99:30-35) are historically used when HCT is the recommended treatment option.

<sup>3</sup>Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: A concise update. Blood 1993;82:691-703.

<sup>4</sup>Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937.

<sup>5</sup>From Jaffe ES, Harris NL, Stein H, et al. WHO Classification of Tumours, Pathology, and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, 2001.

<sup>6</sup>Druker BJ. Chronic Myelogenous Leukemia In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Vol. 2 (ed 8): Lippincott, Williams and Wilkins; 2007:2267-2304.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### MONITORING RESPONSE TO TKI THERAPY AND MUTATIONAL ANALYSIS

Test	Recommendation
Bone marrow cytogenetics <sup>1</sup>	<ul style="list-style-type: none"> <li>• At diagnosis</li> <li>• Failure to reach response milestones</li> <li>• Any sign of loss of response (defined as hematologic or cytogenetic relapse)</li> </ul>
Quantitative RT-PCR (QPCR) using IS	<ul style="list-style-type: none"> <li>• At diagnosis</li> <li>• Every 3 months after initiating treatment. After <i>BCR-ABL1</i> 0.1%–1% (IS) has been achieved, every 3 months for 2 years and every 3–6 months thereafter</li> <li>• If there is 1-log increase in <i>BCR-ABL1</i> transcript levels with MMR, QPCR should be repeated in 1–3 months</li> </ul>
BCR-ABL kinase domain mutation analysis	<ul style="list-style-type: none"> <li>• Chronic phase <ul style="list-style-type: none"> <li>▶ Failure to reach response milestones</li> <li>▶ Any sign of loss of response (defined as hematologic or cytogenetic relapse)</li> <li>▶ 1-log increase in <i>BCR-ABL1</i> transcript levels and loss of MMR</li> </ul> </li> <li>• Disease progression to accelerated or blast phase</li> </ul>

<sup>1</sup>FISH has been inadequately studied for monitoring response to treatment.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### CRITERIA FOR HEMATOLOGIC, CYTOGENETIC, AND MOLECULAR RESPONSE AND RELAPSE

#### Complete hematologic response<sup>1</sup>

- Complete normalization of peripheral blood counts with leukocyte count  $<10 \times 10^9/L$
- Platelet count  $<450 \times 10^9/L$
- No immature cells, such as myelocytes, promyelocytes, or blasts in peripheral blood
- No signs and symptoms of disease with disappearance of palpable splenomegaly

#### Cytogenetic response<sup>2,3</sup>

- Complete cytogenetic response (CCyR) - No Ph-positive metaphases<sup>4</sup>
- Partial cytogenetic response (PCyR) - 1%–35% Ph-positive metaphases
- Major cytogenetic response - 0%–35% Ph-positive metaphases
- Minor cytogenetic response -  $>35\%$  Ph-positive metaphases

#### Molecular response<sup>5,6</sup>

- Early molecular response (EMR) - *BCR-ABL1*  $\leq 10\%$  (IS) at 3 and 6 months
- Major molecular response (MMR) - *BCR-ABL1*  $<0.1\%$  (IS) or  $\geq 3$ -log reduction in *BCR-ABL1* mRNA from the standardized baseline, if QPCR (IS) is not available
- Complete molecular response (CMR) - no detectable *BCR-ABL1* mRNA using a QPCR assay with a sensitivity of at least 4.5 logs below the standardized baseline. CMR is variably described, and is best defined by the the assay's level of sensitivity (eg, MR 4.5).

#### Relapse

- Any sign of loss of response (defined as hematologic or cytogenetic relapse)
- 1-log increase in *BCR-ABL1* transcript levels with loss of MMR should prompt bone marrow evaluation for loss of CCyR but is not itself defined as relapse (eg, hematologic or cytogenetic relapse)

<sup>1</sup>Faderl S et al: Chronic myelogenous leukemia: Biology and therapy. *Ann Intern Med* 1999;131:207-219. The American College of Physicians-American Society of Internal Medicine is not responsible for the accuracy of the translation.

<sup>2</sup>A minimum of 20 metaphases should be examined.

<sup>3</sup>O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2003;348:994-1004.

<sup>4</sup>CCyR typically correlates with *BCR-ABL1*(IS) 0.1%–1%.

<sup>5</sup>Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2003;349:1423-1432.

<sup>6</sup>Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood* 2006;108:28-37.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### DISCONTINUATION OF TKI THERAPY

- Discontinuation of TKI therapy appears to be safe in select CML patients.
- Clinical studies that have evaluated the safety and efficacy of TKI discontinuation have employed strict eligibility criteria and have mandated more frequent molecular monitoring than typically recommended for patients on TKI therapy.
- Some patients have experienced significant adverse events that are believed to be due to TKI discontinuation.
- Discontinuation of TKI therapy should only be performed in consenting patients after a thorough discussion of the potential risks and benefits.
- Outside of a clinical trial, TKI discontinuation should be considered only if ALL of the criteria included in the list below are met.

#### Criteria for TKI Discontinuation

- Age ≥18 years.
- Chronic phase CML. No prior history of accelerated or blast phase CML.
- On approved TKI therapy (imatinib, dasatinib, nilotinib, bosutinib, or ponatinib) for at least three years.
- Prior evidence of quantifiable *BCR-ABL1* transcript.
- Stable molecular response (MR4; *BCR-ABL1* ≤0.01% IS) for ≥2 years, as documented on at least four tests, performed at least three months apart.
- No history of resistance to any TKI.
- Access to a reliable QPCR test with a sensitivity of detection of ≥4.5 logs that reports results on the IS and provides results within 2 weeks.
- Monthly molecular monitoring for the first six months following discontinuation, bimonthly during months 7–24, and quarterly thereafter (indefinitely) for patients who remain in MMR (MR3; *BCR-ABL1* <0.1% IS).
- Prompt resumption of TKI, with a monthly molecular monitoring for the first six months following resumption of TKI and every 3 months thereafter is recommended indefinitely for patients with a loss of MMR. For those who fail to achieve MMR after six months of TKI resumption, *BCR-ABL1* kinase domain mutation testing should be performed, and monthly molecular monitoring should be continued for another six months.
- Consultation with a CML Specialty Center to review the appropriateness for TKI discontinuation and potential risks and benefits of treatment discontinuation, including TKI withdrawal syndrome.
- Reporting of the following to a member of the NCCN CML panel is strongly encouraged:
  - ▶ Any significant adverse event believed to be related to treatment discontinuation.
  - ▶ Progression to accelerated or blast phase CML at any time.
  - ▶ Failure to regain MMR after three months following treatment reinitiation.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**MANAGEMENT OF TOXICITIES**

[BOSUTINIB \(CML-F 1 of 6\)](#)

[DASATINIB \(CML-F 2 of 6\)](#)

[IMATINIB \(CML-F 3 of 6\)](#)

[NILOTINIB \(CML-F 4 of 6\)](#)

[OMACETAXINE \(CML-F 5 of 6\)](#)

[PONATINIB \(CML-F 6 of 6\)](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



**MANAGEMENT OF BOSUTINIB TOXICITY<sup>1</sup>****Dose Adjustments:****Hematologic Toxicities**

- **ANC <1.0 x 10<sup>9</sup>/L or platelets <50 x 10<sup>9</sup>/L:** Hold bosutinib until ANC ≥1.0 x 10<sup>9</sup>/L and platelets ≥50 x 10<sup>9</sup>/L. Resume treatment with bosutinib at the same dose if recovery occurs within 2 weeks. If blood counts remain low for greater than 2 weeks, upon recovery reduce dose by 100 mg and resume treatment. If cytopenia recurs, reduce dose by an additional 100 mg upon recovery and resume treatment. Doses less than 300 mg/d have not been evaluated.
- **Growth factors can be used in combination with bosutinib for patients with resistant neutropenia and thrombocytopenia.**
- **Grade 3-4 anemia:<sup>2</sup>** Check reticulocyte count, ferritin, iron saturation, B12, folate, and correct nutritional deficiencies if present. Transfusion support should be used if patient is symptomatic.

**Non-Hematologic Toxicities**

- **Liver transaminases >5 x IULN:** Hold bosutinib until recovery to ≤2.5 x IULN and resume dose at 400 mg once daily thereafter. If recovery takes longer than 4 weeks, discontinue bosutinib. If transaminase elevations ≥3 x IULN occur concurrently with bilirubin elevations >2 x IULN and alkaline phosphatase <2 x IULN (Hy's law case definition), discontinue bosutinib.
- **Diarrhea:** For NCI CTCAE Grade 3-4 diarrhea (increase of ≥7 stools/day over baseline/pretreatment), withhold bosutinib until recovery to Grade ≤1. Bosutinib may be resumed at 400 mg once daily.
- **For other clinically significant, moderate, or severe non-hematologic toxicity,** withhold bosutinib until the toxicity has resolved, then consider resuming bosutinib at 400 mg once daily. If clinically appropriate, consider re-escalating the dose of bosutinib to 500 mg once daily.

**Special Populations**

- **In patients with pre-existing mild, moderate, and severe hepatic impairment,** the recommended dose of bosutinib is 200 mg daily. A daily dose of 200 mg in patients with hepatic impairment is predicted to result in an area under the curve (AUC) similar to the AUC seen in patients with normal hepatic function receiving 500 mg daily. However, there are no clinical data for efficacy at the dose of 200 mg once daily in patients with hepatic impairment and CML.

**Specific Interventions**

- **Fluid retention events (ie, pulmonary and/or peripheral edema; pleural and pericardial effusion):** diuretics, supportive care.
- **GI upset:** take medication with a meal and large glass of water.
- **Rash:** topical or systemic steroids, dose reduction, interruption, or discontinuation.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [www.fda.gov](http://www.fda.gov).

<sup>2</sup>Although erythropoietin is effective, recent guidelines from the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) do not support the use of erythropoiesis-stimulating agents (ESAs) in myeloid malignancies.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**MANAGEMENT OF DASATINIB TOXICITY<sup>1</sup>****Dose Adjustments:****Hematologic Toxicities**

- **Chronic phase, ANC <0.5 x 10<sup>9</sup>/L or platelets <50 x 10<sup>9</sup>/L:** Hold dasatinib until ANC ≥1.0 x 10<sup>9</sup>/L and platelets ≥50 x 10<sup>9</sup>/L, then resume dasatinib at the starting dose if recovery occurs in ≤7 days. If platelets <25 x 10<sup>9</sup>/L or recurrence of ANC <0.5 x 10<sup>9</sup>/L for >7 days, hold drug until ANC ≥1.0 x 10<sup>9</sup>/L and platelets ≥50 x 10<sup>9</sup>/L, then resume dasatinib at reduced dose of 80 mg once daily for second episode. For third episode, further reduce dose to 50 mg once daily (for newly diagnosed patients) or discontinue dasatinib (for patients with disease that is resistant or intolerant to prior therapy including imatinib).
- **Accelerated phase and blast phase, ANC <0.5 x 10<sup>9</sup>/L and/or platelets <10 x 10<sup>9</sup>/L:** Patients may have cytopenias related to disease. If cytopenia is unrelated to disease, hold dasatinib until ANC ≥1.0 x 10<sup>9</sup>/L and platelets ≥20 x 10<sup>9</sup>/L, and resume at original starting dose. If recurrence, hold dasatinib until ANC ≥1.0 x 10<sup>9</sup>/L and platelets ≥20 x 10<sup>9</sup>/L, and resume dasatinib at reduced dose of 100 mg once daily (second episode) or 80 mg once daily (third episode).
- **Growth factors can be used in combination with dasatinib for patients with resistant neutropenia and thrombocytopenia.**
- **Grade 3-4 anemia:<sup>2</sup>** Check reticulocyte count, ferritin, iron saturation, B12, folate, and correct nutritional deficiencies if present. Transfusion support should be used if patient is symptomatic.

**Non-Hematologic Toxicities**

- **If a severe, non-hematologic, adverse reaction develops with dasatinib, treatment must be held until the event has resolved or improved. Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the initial severity of the event.**

**Rare But Serious Toxicities**

- **Pulmonary arterial hypertension (PAH):** Dasatinib may increase the risk of developing PAH, which may occur anytime after initiation, including after more than one year of treatment. PAH may be reversible on discontinuation of dasatinib. Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating dasatinib and during treatment. If PAH is confirmed, dasatinib should be permanently discontinued.

**Specific Interventions**

- **Fluid retention events (ie, ascites, edema, pleural and pericardial effusion):** diuretics, supportive care.
- **Pleural/pericardial effusion:** diuretics, dose interruption. If patient has significant symptoms, consider short course of steroids (prednisone 20–50 mg/d x 3–4 days, may taper with 20 mg/d x 3–4 days); when resolved, reduce one dose level.
- **GI upset:** Take medication with a meal and large glass of water.
- **Rash:** topical or systemic steroids, dose reduction, interruption, or discontinuation.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [www.fda.gov](http://www.fda.gov).

<sup>2</sup>Although erythropoietin is effective, recent guidelines from the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) do not support the use of erythropoiesis-stimulating agents (ESAs) in myeloid malignancies.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### MANAGEMENT OF IMATINIB TOXICITY<sup>1,3</sup>

#### Dose Adjustments:

##### Hematologic Toxicities

- **Chronic phase, absolute neutrophil count (ANC) <1.0 x 10<sup>9</sup>/L, and/or platelets <50 x 10<sup>9</sup>/L: Hold imatinib until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L, then resume imatinib at the starting dose of 400 mg. If recurrence of ANC <1.0 x 10<sup>9</sup>/L and/or platelets <50 x 10<sup>9</sup>/L, hold drug until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L, then resume imatinib at reduced dose of 300 mg.**
- **Accelerated phase and blast phase, ANC <0.5 x 10<sup>9</sup>/L and/or platelets <10 x 10<sup>9</sup>/L: Patients may have cytopenias related to disease. If cytopenia is unrelated to disease, reduce dose to 400 mg. If cytopenia persists for 2 weeks, reduce dose further to 300 mg. If cytopenia persists for 4 weeks, stop imatinib until ANC ≥1.0 x 10<sup>9</sup>/L and platelet count ≥20 x 10<sup>9</sup>/L and then resume treatment at 300 mg.**
- **Growth factors can be used in combination with imatinib for patients with resistant neutropenia.<sup>4</sup>**
- **Grade 3-4 anemia:<sup>2</sup> Check reticulocyte count, ferritin, iron saturation, B12, folate, and correct nutritional deficiencies if present. Transfusion support should be used if patient is symptomatic.**

##### Non-Hematologic Toxicities

- **Bilirubin >3 x institutional upper limit of normal (IULN) or liver transaminases >5 x IULN: hold imatinib until bilirubin <1.5 x IULN and transaminase levels <2.5 x IULN. Resume imatinib at a reduced daily dose (400 mg to 300 mg, 600 mg to 400 mg, or 800 mg to 600 mg).**
- **Severe hepatotoxicity or severe fluid retention: hold imatinib until the event has resolved. Treatment can be resumed as appropriate depending on the severity of the event.**
- **Patients with moderate renal impairment (CrCl = 20–39 mL/min) should receive a 50% decrease in the recommended starting dose and future doses can be increased as tolerated. Doses greater than 600 mg are not recommended in patients with mild renal impairment (CrCl = 40–59 mL/min). For patients with moderate renal impairment, doses greater than 400 mg are not recommended. Imatinib should be used with caution in patients with severe renal impairment.**

##### Specific Interventions

- **Fluid retention (ie, pleural effusion, pericardial effusion, edema, ascites): diuretics, supportive care, dose reduction, interruption, or discontinuation. Consider echocardiogram to check LVEF.**
- **GI upset: Take medication with a meal and large glass of water.**
- **Muscle cramps: calcium supplement, tonic water.**
- **Rash: topical or systemic steroids, dose reduction, interruption, or discontinuation.**

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [www.fda.gov](http://www.fda.gov).

<sup>3</sup>Many toxicities are self-limiting; consider re-escalating dose at a later time.

<sup>2</sup>Although erythropoietin is effective, guidelines from the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) do not support the use of erythropoiesis-stimulating agents (ESAs) in myeloid malignancies.

<sup>4</sup>Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. *Cancer* 2004;100(12):2592-2597.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### MANAGEMENT OF NILOTINIB TOXICITY<sup>1</sup>

- Nilotinib prolongs the QT interval. Prior to administration of nilotinib and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. ECGs should be obtained to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, as well as following any dose adjustments.
- Sudden deaths have been reported in patients receiving nilotinib.
- Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors.
- Patients should avoid food 2 hours before and 1 hour after taking dose.

#### QT Interval Prolongation

- ECGs with a QTc >480 msec: Hold drug. If serum potassium and magnesium levels are below lower limit of normal, correct with supplements to within normal limits. Review concomitant medication usage. Resume within 2 weeks at prior dose if QTcF is <450 msec and within 20 msec of baseline. If QTcF is between 450 and 480 msec after 2 weeks, resume at reduced dose (400 mg once daily). Following dose reduction, if QTcF returns to >480 msec, nilotinib should be discontinued. ECG should be obtained 7 days after any dose adjustment to monitor QTc.

#### Dose Adjustments:

#### Hematologic Toxicities

- Chronic or accelerated phase, ANC <1.0 x 10<sup>9</sup>/L, and/or platelets <50 x 10<sup>9</sup>/L: Hold nilotinib and monitor blood counts. Resume within 2 weeks at prior dose if ANC >1.0 x 10<sup>9</sup>/L and platelets >50 x 10<sup>9</sup>/L. If blood counts remain low for >2 weeks, reduce dose to 400 mg once daily.
- Growth factors can be used in combination with nilotinib for patients with resistant neutropenia and thrombocytopenia.
- Grade 3–4 anemia:<sup>2</sup> Check reticulocyte count, ferritin, iron saturation, B12, folate, and correct nutritional deficiencies if present. Transfusion support should be used if patient is symptomatic.

#### Non-Hematologic Toxicities

- Elevated serum lipase, amylase, bilirubin, or hepatic transaminases grade ≥3: hold nilotinib and monitor serum levels. Resume nilotinib at 400 mg once daily if serum levels return to grade ≤1.

#### Hepatic Impairment:

- Consider alternate therapies. See prescribing information for dose adjustments related to hepatic impairment.

#### Glucose:

- Assess glucose levels before initiating treatment and monitor treatment as clinically indicated.

#### Rare But Serious Toxicities

- Peripheral arterial occlusive disease (PAOD): Nilotinib is associated with an increased risk of vascular adverse events, including PAOD, and should be used with caution in patients with cardiovascular risk factors or a history of PAOD. Evaluate patients for a history of PAOD and for vascular risk factors prior to initiating nilotinib and during treatment. If PAOD is confirmed, nilotinib should be permanently discontinued.

#### Specific Interventions

- Rash: topical or systemic steroids, dose reduction, interruption, or discontinuation.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [www.fda.gov](http://www.fda.gov).

<sup>2</sup>Although erythropoietin is effective, recent guidelines from the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) do not support the use of erythropoiesis-stimulating agents (ESAs) in myeloid malignancies.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### MANAGEMENT OF OMACETAXINE TOXICITY<sup>1</sup>

#### **Dose Adjustments:**

#### **Hematologic Toxicities**

- Complete blood counts (CBCs) should be performed weekly during induction and initial maintenance cycles. After initial maintenance cycles, monitor CBCs every two weeks or as clinically indicated. ANC  $<0.5 \times 10^9/L$  or platelet count  $<50 \times 10^9/L$ : Delay starting the next cycle until ANC  $\geq 1.0 \times 10^9/L$  and platelet count  $\geq 50 \times 10^9/L$  and reduce the number of dosing days by 2 days for the next cycle.

#### **Non-Hematologic Toxicities**

- Grade 3 or 4 hyperglycemia: Monitor blood glucose levels frequently, especially in patients with diabetes or risk factors for diabetes. Avoid omacetaxine in patients with poorly controlled diabetes mellitus until good glycemic control has been established.
- Manage other clinically significant non-hematologic toxicity symptomatically. Interrupt and/or delay omacetaxine until toxicity is resolved.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [www.fda.gov](http://www.fda.gov).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

### MANAGEMENT OF PONATINIB TOXICITY<sup>1</sup>

- **Vascular occlusion:** Arterial and venous thrombosis and occlusions, including fatal myocardial infarction and stroke, have occurred in patients treated with ponatinib. Monitor for evidence of thromboembolism and vascular occlusion. Interrupt or stop ponatinib immediately for vascular occlusion.
- **Heart failure** has occurred in patients treated with ponatinib. Monitor cardiac function. Interrupt or stop ponatinib for new or worsening heart failure.
- **Hepatotoxicity:** Hepatotoxicity, liver failure, and death have occurred in patients treated with ponatinib. Monitor hepatic function prior to and during treatment. Interrupt ponatinib if hepatotoxicity is suspected.
- **Cardiovascular risk:** Identify and control traditional risk factors for atherosclerosis (eg, diabetes mellitus [DM], hypertension, hyperlipidemia, smoking, estrogen use) before starting ponatinib. Patients with cardiovascular risk factors should be referred to a cardiologist. Consider the use of low-dose aspirin if there is no contraindication.
- Ponatinib is also associated with grade ≥3 skin rash and pancreatitis leading to dose modifications (dose delays or dose reductions).

#### Dosing

- The recommended initial dose of ponatinib is 45 mg once daily. However, an initial starting dose of 30 mg may be a safer and effective dose for patients with risk factors. Safety and efficacy of ponatinib at initial doses lower than 45 mg is being evaluated in a randomized clinical trial.

#### Dose Adjustments:

#### Hematologic Toxicities

- **ANC <1.0 x 10<sup>9</sup>/L or platelets <50 x 10<sup>9</sup>/L**
  - ▶ First occurrence: Hold ponatinib until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L and resume at initial dose of 45 mg.
  - ▶ Second occurrence: Hold ponatinib until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L and resume at 30 mg.
  - ▶ Third occurrence: Hold ponatinib until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L and resume at 15 mg.
- Growth factors can be used in combination with ponatinib for patients with resistant neutropenia and thrombocytopenia.
- **Grade 3-4 anemia:**<sup>2</sup> Check reticulocyte count, ferritin, iron saturation, B12, folate, and correct nutritional deficiencies if present. Transfusion support should be used if patient is symptomatic.

#### Non-Hematologic Toxicities

- **Liver transaminase >3 x ULN (grade ≥2):** Monitor hepatic function. Hold drug until serum levels are <3 x IULN. Resume at lower dose after recovery (30 mg if patient receiving 45 mg; 15 mg if patient receiving 30 mg). Discontinue ponatinib if patient receiving 15 mg.
- **AST or ALT ≥3 x ULN concurrent with bilirubin >2 x ULN and alkaline phosphatase <2 x ULN:** Discontinue ponatinib.

- **Serum lipase elevation, grade 1 or 2 (asymptomatic):** Consider dose interruption or reduction. Serum lipase elevation, grade 3 or 4 (>2 x IULN) (asymptomatic) or asymptomatic radiologic pancreatitis: Hold drug until serum levels are <1.5 x ULN. Resume at lower dose after recovery (30 mg if patient receiving 45 mg; 15 mg if patient receiving 30 mg). Discontinue ponatinib if patient receiving 15 mg.
- **Pancreatitis (symptomatic), grade 3:** Hold drug until serum lipase levels are ≤grade 1. Resume at lower dose after recovery (30 mg if patient receiving 45 mg; 15 mg if patient receiving 30 mg). Discontinue ponatinib if patient receiving 15 mg. Grade 4: Discontinue ponatinib.

#### Rare But Serious Toxicities

- **Hemorrhage:** Hemorrhagic events were reported in clinical trials. Cerebral and gastrointestinal hemorrhage were the most commonly reported serious bleeding events. Serious hemorrhage should be managed with dose interruption.
- **Cardiac arrhythmias:** Advise patients to report signs and symptoms suggestive of alterations in heart rate (fainting, dizziness, chest pain, or palpitations).
- **Tumor lysis syndrome:** Ensure adequate hydration and correct high uric acid levels prior to initiating therapy with ponatinib in patients with advanced-phase CML.

#### Specific Interventions

- **Fluid retention events** (ie, edema, ascites, pleural and pericardial effusion) are managed with dose interruption, dose reduction, or discontinuation of ponatinib as clinically indicated.
- **Hypertension:** Monitor and manage blood pressure elevations.
- **Rash:** topical or systemic steroids, dose reduction, interruption, or discontinuation.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [www.fda.gov](http://www.fda.gov).

<sup>2</sup>Although erythropoietin is effective, recent guidelines from the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) do not support the use of erythropoiesis-stimulating agents (ESAs) in myeloid malignancies.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated on 01/19/17

#### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**All recommendations are category 2A unless otherwise noted.**

#### Table of Contents

<b>Overview</b> .....	<b>MS-2</b>
<b>Literature Search Criteria and Guidelines Update Methodology</b> .....	<b>MS-2</b>
<b>Diagnosis and Workup</b> .....	<b>MS-3</b>
<b>Additional Evaluation</b> .....	<b>MS-3</b>
Chronic Phase CML.....	MS-3
Advanced Phase CML .....	MS-4
<b>Management of Chronic Phase CML</b> .....	<b>MS-4</b>
Primary Treatment.....	MS-4
Treatment Considerations .....	MS-6
Response Milestones after First-Line TKI Therapy .....	MS-11
Resistance to TKI Therapy and BCR-ABL1 Kinase Domain Mutational Analysis .....	MS-12
Second-Line and Subsequent Therapy.....	MS-13

Response Milestones after Second-Line TKI Therapy .....	MS-17
Discontinuation of TKI Therapy .....	MS-18
<b>Management of Advanced Phase CML</b> .....	<b>MS-19</b>
TKI Therapy .....	MS-19
Allogeneic Hematopoietic Cell Transplant.....	MS-20
Treatment Considerations .....	MS-21
Monitoring Response after Allogeneic HCT.....	MS-21
Management of Post-transplant Relapse .....	MS-22
<b>Management of CML During Pregnancy</b> .....	<b>MS-22</b>
TKI Therapy and Conception .....	MS-23
Planning a Pregnancy .....	MS-23
Monitoring and Treatment During Pregnancy.....	MS-24
<b>Specific Considerations for Children with CML</b> .....	<b>MS-24</b>
Selection of TKI.....	MS-24
Monitoring for Long-Term Side Effects.....	MS-25
Immunizations .....	MS-25
<b>Table 1. Summary of Limited Longer-term Follow-up Data from the TKI Discontinuation Trials</b> .....	<b>MS-27</b>
<b>References</b> .....	<b>MS-28</b>

### Overview

Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias. The median age of disease onset is 67 years; however, CML occurs in all age groups (SEER statistics). In 2017, an estimated 8,950 people will be diagnosed with CML in the United States, and 1,080 people will die from the disease.<sup>1</sup>

CML is defined by the presence of Philadelphia chromosome (Ph) in a patient with a myeloproliferative neoplasm (MPN). Ph results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)] that gives rise to a *BCR-ABL1* fusion gene; the product of this fusion gene is a protein with deregulated tyrosine kinase activity (p210) that plays a central role in the pathogenesis of CML.<sup>2</sup> Another fusion protein, p190, is also produced, usually in the setting of Ph-positive acute lymphoblastic leukemia (ALL). p190 is detected only in 1% of patients with CML.<sup>3</sup>

CML occurs in three different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Untreated chronic phase CML (CP-CML) will eventually progress to advanced phase in 3 to 5 years.<sup>4</sup> Gene expression profiling has shown a close correlation of gene expression between the accelerated phase CML (AP-CML) and blast phase CML (BP-CML). The bulk of the genetic changes in progression occur in the transition from CP-CML to AP-CML.<sup>5</sup> The activation of beta-catenin signaling pathway in CML granulocyte-macrophage progenitors (which enhances the self-renewal activity and leukemic potential of these cells) may also be a key pathobiologic event in the evolution to BP-CML.<sup>6</sup>

The NCCN Guidelines for CML discuss the clinical management of CML in all three phases (chronic, accelerated, or blast phase). Evaluation for diseases other than CML as outlined in the NCCN

Guidelines for MPN is recommended for all patients with *BCR-ABL1*-negative MPN.

### Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines® for Chronic Myelogenous Leukemia, an electronic search of the PubMed database was performed to obtain key literature in Chronic Myelogenous Leukemia published between May 2015 and May 2016 using the following search terms: chronic myeloid (or myelogenous) leukemia, chronic phase, accelerated phase, blast phase, advanced phase, tyrosine kinase inhibitors, *BCR-ABL1* mutations, response, monitoring, adherence and discontinuation. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.<sup>7</sup>

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 36 citations and their potential relevance was examined. The data from key PubMed articles selected by the panel for review during the Guidelines update meeting as well as articles from additional sources deemed as relevant to these Guidelines have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN [website](#).



### Diagnosis and Workup (CML-1)

Initial evaluation of patients with CML should consist of a history and physical exam, including palpation of spleen, complete blood count (CBC) with differential, chemistry profile, electrocardiogram (ECG) for QTc prolongation, and hepatitis panel. Bone marrow evaluation (aspirate and biopsy for morphologic review and cytogenetics for the detection of Ph and other chromosomal abnormalities) and molecular testing using quantitative reverse transcriptase polymerase chain reaction (QPCR) to establish the presence of quantifiable *BCR-ABL1* mRNA transcripts at baseline are recommended to confirm the diagnosis of CML.

Bone marrow cytogenetics should be done at initial workup to confirm the disease phase. If collection of bone marrow is not feasible, fluorescence in situ hybridization (FISH) on a peripheral blood specimen with dual probes for *BCR* and *ABL1* genes is an acceptable method to confirm the diagnosis of CML. Interphase FISH is performed on peripheral blood but is associated with a background level of 1% to 5% (depending on the specific probe used in the assay).<sup>8</sup> Hypermetaphase FISH is more sensitive and can analyze up to 500 metaphases at a time but it is applicable only to dividing cells in the bone marrow.<sup>9</sup> Double-fusion FISH is also associated with low false-positive rates and can detect all variant translocations of the Ph-chromosome.<sup>10</sup>

QPCR (peripheral blood) is the most sensitive assay available for the measurement of *BCR-ABL1* mRNA and it can detect one CML cell in a background of  $\geq 100,000$  normal cells. QPCR assay reports the actual percentage of *BCR-ABL1* mRNA transcripts and the results are expressed as the ratio of *BCR-ABL1* transcript numbers to the number of control gene transcripts.<sup>11,12</sup> Alternatively, this ratio is also

expressed as a percentage whereby equal copy numbers of the *BCR-ABL1* gene and the control gene at diagnosis would be expressed as 100%.<sup>12</sup> Thus, the choice of an appropriate control gene is important for generating reliable and reproducible data. *BCR*, *ABL1*, beta-glucuronidase (*GUSB*), and beta-2-microglobulin (*B2M*) have been widely studied for *BCR-ABL1* quantification.<sup>13,14</sup> *BCR* was used as the control gene in the IRIS trial.<sup>13</sup>

*BCR-ABL1* transcripts in the peripheral blood at very low levels (1–10 out of  $10^8$  peripheral blood leukocytes) can also be detected in approximately 30% of normal individuals, and the incidence of *BCR-ABL1* transcripts increases with advancing age in healthy individuals.<sup>15,16</sup> Tyrosine kinase inhibitor (TKI) is not indicated, as the risk of developing CML for these individuals is extremely low.

### Additional Evaluation

#### Chronic Phase CML

Determination of risk score (using either the Sokal or Hasford scoring systems) prior to initiation of treatment with tyrosine kinase inhibitors (TKIs) is recommended for patients diagnosed with chronic phase CML. Sokal and Hasford (Euro) scoring systems stratify patients into three risk groups (low, intermediate, and high) and have been used for the risk stratifications of patients in clinical trials evaluating TKIs.<sup>17,18</sup> The Sokal score is based on the patient's age, spleen size, platelet count, and percentage of blasts in the peripheral blood.<sup>17</sup> The Euroscore includes eosinophils and basophils in the peripheral blood in addition to the same clinical variables used in the Sokal score.<sup>18</sup>

European Treatment and Outcome Study (EUTOS) score is based only on the percentage of basophils in the blood and spleen size. The predictive value of EUTOS score was validated in a cohort of 2060

patients enrolled in studies of first-line treatment with imatinib-based regimens.<sup>19</sup> EUTOS score was better than Sokal and Hasford score in predicting the probability of achieving CCyR at 18 months and 5-year progression-free survival (PFS). However, the predictive value of EUTOS score has not been confirmed in subsequent studies by other investigators.<sup>20-22</sup> Additional studies are necessary to validate the EUTOS score for predicting clinical outcomes of patients receiving TKI therapy.

### Advanced Phase CML

Flow cytometry to determine cell lineage, mutational analysis, and HLA testing, if considering allogeneic HCT, are recommended for patients with advanced-phase CML.

The revised 2016 WHO diagnostic criteria for AP-CML include a “provisional” response to TKI criteria in addition to hematologic and cytogenetic criteria.<sup>23</sup> These diagnostic criteria require validation in prospective clinical trials. It should be noted that clinical trials of TKIs have largely reported efficacy data using the modified MD Anderson Cancer Center accelerated phase criteria (15% and <30% peripheral blood or bone marrow blasts, ≥ 30% or more of peripheral blood blasts and promyelocytes, ≥ 20% peripheral blood or bone marrow basophils, platelet count ≤100 x 10<sup>9</sup>/L unrelated to therapy, and clonal evolution).<sup>24</sup>

Clonal evolution, defined by the presence of additional chromosomal abnormalities (trisomy 8, isochromosome 17, trisomy 19, abnormalities of 3q26.2, second Ph and complex abnormalities) besides the Ph, is associated with unfavorable prognosis.<sup>25-29</sup> Clonal evolution is considered to be a feature of AP-CML and has a significant adverse impact when associated with other features of accelerated phase.<sup>28</sup> However, clonal evolution is associated with a better prognosis when it is considered as the only criteria for accelerated phase.<sup>25</sup> Clonal

cytogenetic abnormalities in Ph-negative cells have also been reported in a small subset of patients during the course of imatinib therapy.<sup>30-35</sup> The significance of these chromosomal abnormalities is unclear, but the most common abnormalities include trisomy 8 and loss of Y chromosome. The overall prognosis for patients with Ph-negative CML and clonal cytogenetic evolution seems to be good and is dependent on response to imatinib therapy.<sup>34</sup> The exceptions are chromosome 7 abnormalities, particularly monosomy 7, where progression to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have been reported.<sup>36,37</sup>

The WHO diagnostic criteria define blast phase as the presence of ≥20% blast cells in the peripheral blood or bone marrow, the presence of extramedullary blast proliferation, and large foci or clusters of blasts in the bone marrow biopsy.<sup>23</sup> The International Bone Marrow Transplant Registry (IBMTR) criteria define blast phase as the presence of ≥30% blasts in the blood, bone marrow, or both, or as the presence of extramedullary disease.<sup>38</sup> The same definition was used in most of the clinical trials leading to the approval of TKIs.

## Management of Chronic Phase CML (CML-2 and CML-3)

### Primary Treatment

#### *Imatinib*

In the IRIS trial 1106 patients with newly diagnosed CP-CML were randomized to receive either imatinib 400 mg or interferon-alpha plus low-dose cytarabine. After a median follow-up of 60 months, the estimated 5-year overall survival (OS) rate and the best observed major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) rates were 89%, 89%, and 82%, respectively.<sup>39</sup> The estimated rates of 8-year event-free survival (EFS), Freedom-from-progression (FFP) to accelerated or blast phase, and 8-year OS were 81%, 92%,

and 85%, respectively.<sup>40</sup> The overall rate of progression to accelerated or blast phase was 0.4%. The rate of major molecular response (MMR; <0.1% *BCR-ABL1* IS) increased from 24% at 6 months to 39% at 12 months, and the best observed MMR rate was 86% and none of the patients with documented MMR at 12 months progressed to accelerated or blast phase. In an analysis that evaluated the safety and efficacy of imatinib in 359 patients who crossed over from interferon-alpha plus cytarabine to imatinib in the IRIS study, after a median follow-up of 54 months on imatinib, MCyR and CCyR were observed in 86% and 81% of patients, respectively. Estimated rates of FFP to accelerated or blast phase and OS at 48 months were 91% and 89%, respectively.<sup>41</sup>

Several studies have evaluated the efficacy of high-dose imatinib in newly diagnosed patients.<sup>42-46</sup> In the TOPS study, although imatinib 800 mg induced higher and faster CCyR and MMR compared to imatinib 400 mg early on, there is no difference in response rates between the two arms at 12 months and beyond.<sup>44</sup> After a minimum follow-up of 42 months, the MMR rates were 75.8% and 79.0% for 400 mg and 800 mg respectively ( $P = .4807$ ). Other studies have reported higher MMR rates at 12 months for imatinib 800 mg.<sup>45,46</sup> In the CML IV study, after a median follow-up of 7 years, the cumulative incidence of deep molecular response (MR4.0) were higher for imatinib 800 mg (66% vs. 56% for imatinib 400 mg).<sup>45</sup> The SWOG (S0325) study also reported higher rates of MR4.0 with imatinib 800 mg at 12 months (25% vs. 10% respectively,  $P = .038$ ).<sup>46</sup> However, imatinib 800 mg was not associated with lower rates of disease progression than imatinib 400 mg in any of the studies, despite improved early responses. Imatinib 800 mg was associated with higher rates of dose interruption, reduction, or discontinuation in a substantial number of patients due to grade 3 or 4 adverse events in all of the studies. However, patients who

can actually tolerate the higher dose of imatinib do achieve better response rates than those receiving standard-dose imatinib. Given the recent data showing superior efficacy of nilotinib and dasatinib in newly diagnosed patients, imatinib 800 mg is not recommended as initial therapy.

### Dasatinib

In the DASISION study, 519 patients with newly diagnosed CP-CML were randomized to receive dasatinib (100 mg once daily; 259 patients) or imatinib (400 mg once daily; 260 patients). In the final 5-year analysis, the rates of CCyR (83% vs. 78%;  $P = .187$ ), MMR ( $\leq 0.1\%$  *BCR-ABL1* IS; 76% vs. 64%;  $P = .002$ ), and MR4.5 (42% vs. 33%;  $P = .025$ ) were significantly higher with dasatinib than with imatinib.<sup>47</sup> The proportion of patients achieving  $\leq 10\%$  *BCR-ABL1* IS at 3 months was also higher with dasatinib (84% vs. 64%) and fewer patients transformed to accelerated or blast phase on dasatinib (12 patients; 4.6%) than on imatinib (19 patients; 7.3%). The estimated 5-year PFS (85% vs. 86%) and OS (91% vs. 90%) rates were similar for dasatinib and imatinib.<sup>47</sup>

The 3-year follow-up results of the Intergroup phase II randomized trial (S0325;  $n = 250$ ) also confirmed that dasatinib (100 mg once daily) induced more CCyR and deeper molecular responses, compared with imatinib (400 mg once daily) in patients with newly diagnosed CP-CML.<sup>48</sup> The molecular response rates (3-log reductions in *BCR-ABL1* transcript level) at 12 months were 59% and 44%, respectively, for dasatinib and imatinib ( $P = .059$ ) and the estimated 3-year OS (97% for both dasatinib and imatinib) and PFS (93% for dasatinib and 90% for imatinib) rates were similar in both arms.

### **Nilotinib**

The ENESTnd study compared the safety and efficacy of nilotinib at two different dose levels (300 mg twice daily; n = 282 or 400 mg twice daily; n = 281) with that of imatinib (400 mg once daily; n = 283) in patients with newly diagnosed CP-CML. At 5 years, significantly more patients in the nilotinib arms had achieved MMR (77% for nilotinib 300 mg and 400 mg twice daily vs. 60% for imatinib 400 mg once daily;  $P < .0001$ ) and MR4.5 (54% for nilotinib 300 mg twice daily, 52% for nilotinib 400 mg twice daily vs. 31% for imatinib 400 mg once daily;  $P < .0001$ ).<sup>49</sup> Fewer patients progressed to accelerated or blast phase in the nilotinib arm (10 patients treated with nilotinib 300 mg twice daily and 6 patients treated with nilotinib 400 mg twice daily) than in the imatinib arm (21 patients). The estimated 5-year OS rates were 93.7%, 96.2%, and 91.7%, respectively. The corresponding 5-year PFS rates were 92.2%, 95.8%, and 91%, respectively.

### **Bosutinib**

In the phase III randomized trial (BELA trial; n = 500), although bosutinib resulted in higher MMR rate (47% vs. 41% for imatinib;  $P < .001$ ) and fewer transformations to AP-CML or BP-CML at 24 months (2% vs. 4% on imatinib) in newly diagnosed patients with CP-CML than imatinib 400 mg, there was no difference in CCyR rate at 12 months between the 2 treatment arms (70% and 68%, respectively, for bosutinib and imatinib;  $P = .601$ ).<sup>50</sup> Bosutinib is not recommended as first-line therapy for newly diagnosed patients with CP-CML.

### **Treatment Considerations (CML-2)**

The selection of first-line TKI therapy in a given patient should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. Allogeneic HCT is no longer recommended as a first-line treatment option for patients with CP-CML.

### **Treatment Recommendations Based on Risk Stratification**

Long-term follow-up data from DASISION and ENESTnd studies have shown that dasatinib or nilotinib are associated with higher rates of molecular response and lower risk of disease progression than imatinib in intermediate- and high-risk patients, suggesting that this group of patients may preferentially benefit from dasatinib or nilotinib.<sup>47,49</sup> In the DASISION study, the MMR rates were higher for dasatinib than for imatinib in patients with intermediate (71% and 65%, respectively) and high (67% and 54% respectively) Hasford (Euro) risk scores and achievement of MMR after first-line dasatinib is associated with reduced risk of progression AP or BP.<sup>47,51</sup> In the ENESTnd study, fewer patients with intermediate and high Sokal risk score progressed to AP or BP in the nilotinib arm (2 patients with intermediate risk score and 7 patients with high risk score) than in the imatinib arm (10 patients with intermediate risk score and 11 patients with high risk score).<sup>49</sup> The estimated 5-year PFS rates were 93% and 86% for patients with intermediate-, and high-risk scores respectively in the nilotinib arm. The corresponding PFS rates for imatinib were 88% and 82.6% respectively.

Dasatinib (100 mg once daily), imatinib (400 mg daily) and nilotinib (300 mg twice daily) are included as options (category 1) for primary treatment in patients with low-risk score. Nilotinib and dasatinib are preferred for patients with intermediate or high risk scores.

Since both dasatinib and nilotinib have very good efficacy in the upfront setting, differences in their potential toxicity profiles would be helpful in the selection of either one of these TKIs over imatinib in patients with low-risk score. Dasatinib may be preferred in patients with a history of arrhythmias, heart disease, pancreatitis, or hyperglycemia. Nilotinib may be preferred for patients with a history of lung disease or deemed to be at risk of developing pleural effusions.

### Toxicity Profile

#### Dasatinib

Nonhematologic adverse events are mild to moderate and most of the adverse events are manageable with dose modification. The incidences of grade 3 or 4 cytopenias (neutropenia, 29% vs. 24%; anemia, 13% vs. 9%; and thrombocytopenia, 22% vs. 14%) were higher with dasatinib compared to imatinib.

Pleural effusion is an adverse effect of dasatinib. In the DASISION study, drug-related pleural effusion was more common with dasatinib (28%) than with imatinib (0.8%).<sup>47</sup> The incidences of pleural effusion are higher in patients with advanced phase CML (occurring in 50% of patients with AP-CML, and 33% of patients with BP-CML compared to 29% of patients with CP-CML.<sup>52</sup> The occurrence of pleural effusion is significantly reduced with dasatinib 100 mg once daily compared with 70 mg twice daily.<sup>53</sup> Lymphocytosis related to dasatinib treatment has been associated with increased incidences of pleural effusion and improved cytogenetic response rates.<sup>54</sup> Patients with prior cardiac history, hypertension, and those receiving twice-daily dosing of dasatinib at 70 mg are at increased risk of developing pleural effusions. Close monitoring and timely intervention are necessary for patients at risk of developing pleural effusions. Dasatinib is also associated with significant but reversible inhibition of platelet aggregation that may contribute to bleeding in some patients, especially if accompanied by thrombocytopenia.<sup>55</sup>

Reversible pulmonary arterial hypertension has been reported as a rare but serious side effect associated with dasatinib.<sup>56,57</sup> In the DASISION study, pulmonary hypertension was reported in 5% of patients compared to 0.4% of patients treated with imatinib.<sup>47</sup> Evaluation for signs and symptoms of underlying cardiopulmonary disease prior to initiating and during treatment with dasatinib is recommended. If

pulmonary arterial hypertension is confirmed, dasatinib must be permanently discontinued.

The recommended starting dose of dasatinib is 100 mg once daily for patients with CP-CML. Data from case reports and retrospective analysis suggest that lower doses of dasatinib (20 mg–120 mg) may potentially have similar efficacy.<sup>58,59</sup> Treatment interruption of dasatinib at standard dose and reintroduction of dasatinib at a lower dose of 40 mg twice daily also resolved all pulmonary complications without recurrence.<sup>60</sup> However, the minimum effective dose has not been established in randomized clinical trials. Initiation of dasatinib at 50 mg (20 mg with careful monitoring in selected patients) should be considered for patients with clinically significant intolerance to dasatinib at 100 mg once daily to avoid serious adverse events necessitating the discontinuation of dasatinib (eg, pleural effusion, myelosuppression).

#### Imatinib

Imatinib (400 mg daily) is generally well tolerated. Most frequently reported non-hematologic adverse events include gastrointestinal disturbances, edema, rash, and musculoskeletal complaints. Skin hypopigmentation has also been reported as a benign side effect of imatinib and is reversible upon discontinuation or dose reduction.<sup>61,62</sup> Chronic fatigue (mostly correlated with musculoskeletal pain and muscular cramps) is a major factor reducing quality of life.<sup>63</sup> Hypophosphatemia and decrease in bone mineral density has been noted in a small group of patients, suggesting that monitoring bone health should be considered for patients taking imatinib.<sup>64,65</sup>

#### Nilotinib

Fluid retention, pleural effusion, pericardial effusion, pulmonary edema, or muscle cramps were less common with nilotinib than with imatinib. Neutropenia and thrombocytopenia (grade 3-4) were reported only in

12% and 10% of patients treated with nilotinib 300 mg twice daily. Grade 3 or 4 elevations in lipase and bilirubin, hypophosphatemia, and hyperglycemia were observed in 9%, 4%, 8%, and 7% of patients, respectively. Patients with a previous history of pancreatitis may be at greater risk of elevated serum lipase. However, these abnormalities were transient and clinically asymptomatic.

Nilotinib labeling contains a black box warning regarding the risk of QT interval prolongation, and sudden cardiac death has been reported in patients receiving nilotinib. QT interval prolongation could be managed with dose reduction. Electrolyte abnormalities should be corrected prior to initiation of treatment with nilotinib and should be monitored periodically. Drugs that prolong QT interval should be avoided. ECG should be obtained to monitor the QT interval at baseline, 7 days after initiation of nilotinib and periodically thereafter, as well as following any dose adjustments.

Nilotinib is associated with an increased risk of peripheral arterial occlusive disease (PAOD).<sup>66-68</sup> Patients should be evaluated for pre-existing PAOD and vascular risk factors prior to initiating and during treatment with nilotinib. If PAOD is confirmed, nilotinib should be permanently discontinued. Patients with cardiovascular risk factors should be referred to a cardiologist.

### **Drug Interactions**

Dasatinib, imatinib, and nilotinib are metabolized in the liver by cytochrome P450 (CYP) enzymes. Drugs that induce or inhibit CYP3A4 or CYP3A5 enzymes may alter the therapeutic effect of TKIs.<sup>69</sup> CYP3A4 or CYP3A5 inducers may decrease the therapeutic plasma concentration of TKIs whereas CYP3A4 inhibitors and drugs that are metabolized by the CYP3A4 or CYP3A5 enzyme might result in increased plasma levels of TKIs. In addition, imatinib is also a weak

inhibitor of the CYP2D6 and CYP2C9 isoenzymes and nilotinib is a competitive inhibitor of CYP2C8, CYP2C9, CYP2D6, and UGT1A1, potentially increasing the plasma concentrations of drugs eliminated by these enzymes. Concomitant use of drugs that are metabolized by these enzymes should be used with caution and appropriate alternatives should be explored to maximize treatment outcome. If coadministration cannot be avoided, dose modification should be considered. Concomitant use with H2 blockers or proton pump inhibitors (PPIs) is not recommended in patients receiving dasatinib.

### **Management of Hematologic Toxicities of TKI Therapy**

Cytopenias (anemia, neutropenia, and thrombocytopenia) should be managed with transient interruptions of TKI therapy and dose modifications. Please see the package insert for full prescribing information available at [www.fda.gov](http://www.fda.gov), for the recommended dose modifications of specific TKI therapy. Routine monitoring of reticulocyte count, ferritin, iron saturation, B12, and folate and correction of nutritional deficiencies if present, is recommended for patients with grade 3-4 anemia. Transfusion support should be used in symptomatic patients. Growth factor support can be used in combination with TKI therapy for the management of neutropenia.<sup>70,71</sup> The use of erythropoiesis-stimulating agents (ESAs) did not impact survival or cytogenetic response rate, but was associated with a higher thrombosis rate in patients with CP-CML.<sup>72</sup> Recent guidelines from the U.S. Centers for Medicare & Medicaid Services (CMS) and the FDA do not support the use of ESAs in patients with myeloid malignancies.

### **Adherence to Therapy**

Treatment interruptions and non-adherence to therapy may lead to undesirable clinical outcomes.<sup>73-75</sup> In the ADAGIO study, non-adherence to imatinib was associated with poorer response and patients with suboptimal response had significantly higher mean percentages of

imatinib not taken (23%) than did those with optimal response (7%).<sup>73</sup> Marin and colleagues identified adherence as the only independent predictor for achieving complete molecular response (CMR) on standard-dose imatinib.<sup>74</sup> Patients whose imatinib doses were increased had poor adherence (86%), and in these patients adherence was the only independent predictor for inability to achieve an MMR. Poor adherence to imatinib therapy has also been identified as the most important factor contributing to cytogenetic relapse and imatinib failure.<sup>75</sup> Patients with an adherence rate of 85% or less had a higher probability of losing their CCyR at 2 years than those with an adherence rate of more than 85% (27% and 1.5%, respectively). *BCR-ABL1* doubling time has been reported as a marker to identify non-adherence to TKI therapy in patients with CP-CML.<sup>76</sup>

Poor adherence to therapy has also been reported in patients receiving dasatinib and nilotinib following imatinib failure.<sup>77,78</sup> However, the impact of non-adherence to dasatinib and nilotinib on treatment efficacy has not yet been reported. In the absence of such data, findings from the studies involving patients treated with imatinib should be extrapolated to patients receiving second-generation TKI therapy.

Patient education on adherence to therapy and close monitoring of patient's adherence is critical to achieve optimal responses. In a significant proportion of patients with TKI-induced toxicities, responses have been observed with doses well below their determined maximum tolerated doses.<sup>79</sup> Short interruptions or dose reductions, when medically necessary, may not have a negative impact on the control of disease or other outcomes. Adequate and appropriate management of side effects and scheduling appropriate follow-ups to review side effects may be helpful to improve patient adherence to therapy.<sup>80</sup>

### **Monitoring Response to TKI Therapy**

Response to TKI therapy is determined by the measurement of hematologic (normalization of peripheral blood counts), cytogenetic (decrease in the number of Ph-positive metaphases using bone marrow cytogenetics), and molecular responses (decrease in the amount of *BCR-ABL1* chimeric mRNA using QPCR). The goal of TKI therapy is to achieve a CCyR within 12 months of initiation of therapy and to prevent disease progression to accelerated or blast phase.

Conventional bone marrow cytogenetics is the standard method for monitoring cytogenetic responses and clinical trial response analyses are most often based on conventional bone marrow cytogenetics. If conventional bone marrow cytogenetics showed no analyzable metaphases, cytogenetic response can be evaluated by FISH; however, it has a false-positive rate of 1% to 10%.<sup>81,82</sup> Although some investigators have reported that interphase FISH can be used to monitor CCyR, endpoints for TKI failure have not been defined on the basis of FISH analysis.<sup>83,84</sup> The panel feels that FISH has been inadequately studied for monitoring response to TKI therapy. Therefore, FISH is not generally recommended for monitoring response if conventional cytogenetics or QPCR are available.

QPCR is the only tool capable of monitoring responses after the patient has achieved CCyR since *BCR-ABL1* transcripts typically remain detectable after CCyR is achieved. A major advantage of the QPCR is the strong correlation between the results obtained from the peripheral blood and the bone marrow, allowing molecular monitoring without the necessity of obtaining bone marrow aspirations.<sup>85,86</sup>

### **Standardization of Molecular Monitoring Using the International Scale**

In 2006, the National Institutes of Health Consensus Group proposed the use of an International Scale (IS) to standardize molecular

monitoring with QPCR across different laboratories.<sup>12</sup> This group recommended the use of one of three control genes (*BCR*, *ABL1*, or *GUSB*) and a QPCR assay with a sensitivity of at least 4-log reduction from the standardized baseline.

In the IS, the standardized baseline (defined as the median value of *BCR-ABL1* mRNA at the time of diagnosis in 30 CML patients as established in the IRIS study) is taken to represent 100%. MMR, 3-log reduction in the *BCR-ABL1* transcripts from this standardized baseline, is fixed at 0.1%.<sup>12,87,88</sup> A 2-log reduction (1% *BCR-ABL1* IS) from the standardized baseline generally correlates with CCyR. CMR is defined as undetectable *BCR-ABL1* transcripts as assessed by QPCR with a sensitivity of 4.5-log reduction or more from the standardized baseline. CMR is variably described, and is best defined by the assay's level of sensitivity. The *BCR-ABL1* transcripts obtained in a given laboratory are converted to the IS by applying a laboratory-specific conversion factor (CF).<sup>12,89</sup> Typically each laboratory has to exchange 20 to 30 pre-treatment samples with a reference laboratory, to obtain a laboratory-specific CF. Both laboratories analyze the samples and the results are plotted on a log scale for comparison. The antilog of the estimated mean bias between the methods is designated as the CF.<sup>89</sup> Once a laboratory-specific CF is established, it is validated again through a second sample exchange with the reference laboratory.

QPCR (IS) is still not available in many laboratories because the process is relatively cumbersome, time consuming, and is not seen as practical if the laboratory does not have a high volume of assays to perform, or if the prescribing physicians do not demand it. Alternatively, laboratories with no access to QPCR (IS) may establish their own standardized baseline, based on a large number of pre-treatment samples. Molecular response to TKI therapy is then measured as the log-reduction of *BCR-ABL1* mRNA from the standardized baseline (not

a reduction from the actual baseline level in an individual patient). This is an effective method, and was used in the IRIS trial to establish the 3-log reduction in the *BCR-ABL1* transcripts from the standardized baseline (not a reduction from the actual baseline level in an individual patient) as the MMR.<sup>13</sup> In addition, this technique was recently used in the U.S. Intergroup CML trial.<sup>48</sup> The findings from the post hoc analyses of the RIGHT study also confirmed the feasibility of this technique.<sup>86</sup> The probability of achieving MMR at 18 months was higher in patients with >2-log reduction in *BCR-ABL1* levels at 3, 6, and 9 months than those with ≤2-log reduction.<sup>86</sup>

### **Recommendations for Monitoring Response to TKI Therapy (CML-D)**

QPCR (IS) is the preferred method to monitor response to TKI therapy. QPCR assays with a sensitivity of ≥4.5-log reduction from the standardized baseline are recommended for the measurement of *BCR-ABL1* transcripts. If QPCR (IS) is not available, it is acceptable to use the log-reduction from the laboratory-specific standardized baseline to monitor molecular response. In patients with prolonged myelosuppression who may not be in complete hematologic response (CHR) due to persistent cytopenias or unexplained drop in blood counts during therapy, bone marrow cytogenetics may be useful to confirm response to TKI therapy and exclude other pathology, such as MDS or the presence of chromosomal abnormalities other than Ph.

Monitoring with QPCR (IS) every 3 months is recommended for all patients after initiating TKI therapy, including those who meet response milestones at 3, 6, and 12 months (1% to 10% *BCR-ABL1* IS at 3 and 6 months, 0.1% to <1% *BCR-ABL1* IS at 12 months and <0.1% *BCR-ABL1* IS at 18 months). After CCyR has been achieved, molecular monitoring is recommended every 3 months for 2 years and every 3 to 6 months thereafter.



Frequent molecular monitoring with QPCR (IS) can help to identify non-adherence to TKI therapy early in the treatment course.<sup>90</sup> Since adherence to TKI therapy is associated with better clinical outcomes, frequent molecular monitoring is essential if there are concerns about the patient's adherence to TKI therapy after CCyR has been achieved. In patients with deeper molecular responses (MMR and below) and who are compliant with TKI therapy, the frequency of molecular monitoring could be reduced, though the optimal frequency is unknown.

### Response Milestones after First-Line TKI Therapy

Early molecular response ( $\leq 10\%$  *BCR-ABL1* IS after 3 months or  $\leq 1\%$  *BCR-ABL1* IS at 6 months) after first-line TKI therapy has emerged as an effective prognostic indicator of long-term outcomes.<sup>47,49,91-93</sup>

In an analysis of 282 patients with CP-CML treated with imatinib 400 mg as first-line therapy, patients with  $\leq 9.84\%$  *BCR-ABL1* IS at 3 months had significantly higher rates of OS, PFS, and EFS at 8 years than patients with  $>9.84\%$  *BCR-ABL1* IS at 3 months ( $P < .001$ ).<sup>91</sup> The OS, PFS, and EFS rates were 93.3%, 92.8%, and 65%, respectively, for patients with  $\leq 9.84\%$  *BCR-ABL1* IS at 3 months compared to 56.9%, 57%, and 6.9%, respectively, for those with  $>9.84\%$  *BCR-ABL1* IS. In the CML IV study (1,303 newly diagnosed patients treated with imatinib),  $>10\%$  *BCR-ABL1* IS at 3 months and  $>1\%$  *BCR-ABL1* IS at 6 months after imatinib correlated with significantly lower OS and PFS rates at 5 years. At 3 months, the 5-year OS rate was 87% for patients with a  $>10\%$  *BCR-ABL1* IS compared to 95% for those who achieved  $\leq 10\%$  *BCR-ABL1* at 3 months ( $P < .0001$ ).<sup>92</sup> The 5-year PFS rates were 87% and 92%, respectively ( $P = .037$ ). Similarly, at 6 months, the 5-year OS rate was 89% for those with a  $>1\%$  *BCR-ABL1* IS compared to 97% for patients with *BCR-ABL1*  $\leq 1\%$  IS ( $P < .0001$ ). The

corresponding 5-year PFS rates were 89% and 96%, respectively ( $P = .006$ ).

In the DASISION study, patients who achieved  $\leq 10\%$  *BCR-ABL1* IS at 3 months were more likely to achieve CCyR, MMR, and MR4.5 by 5 years and they also had higher rates of PFS and OS rates in both treatment arms.<sup>47</sup> In the dasatinib arm, the 5-year response rates for CCyR, MMR, and MR4.5 were 94%, 87%, and 54%, respectively, for patients with  $\leq 10\%$  *BCR-ABL1* IS at 3 months compared to 41%, 38%, and 5%, respectively, for those with  $>10\%$  *BCR-ABL1* IS at 3 months. In the imatinib arm, the corresponding response rates were 92%, 81%, and 48%, respectively, for patients with  $\leq 10\%$  *BCR-ABL1* IS at 3 months compared to 59%, 41%, and 12% for patients with  $>10\%$  *BCR-ABL1* IS at 3 months. The 5-year PFS rates for patients with *BCR-ABL1*  $\leq 10\%$  and  $>10\%$  at 3 months were 89% and 72%, respectively, for dasatinib ( $P = .0014$ ) and 93% and 72%, respectively, for imatinib ( $P < .001$ ).<sup>47</sup> The corresponding 5-year OS rates were 94% and 84%, respectively, for dasatinib ( $P = .0028$ ) and 95% and 80.5%, respectively, for imatinib ( $P < .001$ ). The rates of transformation to accelerated or blast phase were also lower among patients who achieved  $\leq 10\%$  *BCR-ABL1* IS at 3 months (3% for dasatinib and 15% for imatinib) vs.  $>10\%$  *BCR-ABL1* IS at 3 months (14% for dasatinib and 15% for imatinib) in both treatment arms.

In the ENESTnd study,  $>10\%$  *BCR-ABL1* IS at 3 months was associated with lower rates of MR4.5, an increased risk of progression, and lower PFS and OS.<sup>49</sup> Patients who achieved  $>1\%$  to  $\leq 10\%$  *BCR-ABL1* at 3 months were more likely to achieve MR4.5 by 5 years than those with  $>10\%$  *BCR-ABL1* at 3 months (52% vs. 8% on nilotinib 300 mg twice daily,  $P < .0001$ ; 42% vs. 21% on nilotinib 400 mg twice daily,  $P = .0001$  and 34% vs. 16% on imatinib,  $P < .0001$ ). The estimated 5-year PFS rates (95.3% vs. 78.3% for nilotinib 300 mg twice

daily,  $P = .0014$ ; 95.7% vs. 89.0% for nilotinib 400 mg twice daily,  $P = .0597$ ; 98.5% vs. 79.3% for imatinib,  $P < .0001$ ) and OS rates (97.6% and 81.9%, respectively, for nilotinib 300 mg twice daily;  $P = .0005$ ; 95.7% and 92.7%, respectively, for nilotinib 400 mg twice daily;  $P = .5256$  and 99.2% and 79.1%, respectively, for imatinib;  $P < .0001$ ) were significantly higher for patients with  $>1\%$  to  $\leq 10\%$  *BCR-ABL1* than those with  $>10\%$  *BCR-ABL1* at 3 months.

Achievement of CCyR (0.1% to  $<1\%$  *BCR-ABL1* IS) at 12 months after first-line TKI therapy is an established prognostic indicator of long-term survival.<sup>39,94</sup> In the IRIS study, at the median follow-up of 60 months, PFS rate was better for patients who achieved a CCyR or PCyR at 12 months compared to those who did not have a MCyR at 12 months (97%, 93%, and 81%, respectively).<sup>39</sup> In an analysis of patients with newly diagnosed CP-CML treated with imatinib or second-generation TKIs, the 3-year EFS and OS rates were 98% and 99% for patients who achieved CCyR at 12 months compared to 67% and 94% in patients who did not achieve a CCyR.<sup>94</sup>

Achievement of MMR is associated with durable long-term cytogenetic remission and a lower rate of disease progression.<sup>39</sup> However, it may not be of prognostic significance in patients who are in CCyR.<sup>85,95-100</sup> In the 7-year follow-up data from the IRIS study, among patients who were in CCyR, achievement of MMR at 12 months had no significant impact on EFS or OS but the achievement of MMR at 18 months was associated with a modest but statistically significant benefit for EFS. The EFS rate was 95% for patients with MMR ( $< 0.1\%$  *BCR-ABL1*) at 18 months compared with 86% for patients with  $>0.1\% \leq 1\%$  *BCR-ABL1* at 18 months.<sup>85</sup> In the German CML IV study, MMR at 12 months was associated with a better PFS (99% vs. 94%;  $P = .0023$ ) and OS (99% vs. 93%;  $P = .0011$ ) at 3 years when compared with  $>1\%$  *BCR-ABL1* IS or no MMR.<sup>98</sup> However, there was no difference in PFS

and OS when compared with the 0.1% to 1% *BCR-ABL1* IS group (which closely correlates with CCyR).<sup>98</sup> The 3-year survival rates for MMR at 12 months and 0.1% to 1% *BCR-ABL1* IS at 12 months were 99% and 98%, respectively, implying that MMR is not of prognostic significance in patients who have achieved CCyR at 12 months. The achievement of MMR is also not a significant prognostic indicator of outcome in patients who are in stable CCyR after first-line treatment with dasatinib or nilotinib.<sup>99,100</sup> Although some investigators have reported that dose escalation of imatinib might benefit patients in CCyR with no MMR,<sup>101</sup> there are no randomized studies to show that a change of therapy would improve survival, PFS, or EFS in this group of patients.<sup>102</sup>

### Resistance to TKI Therapy and *BCR-ABL1* Kinase Domain Mutational Analysis

#### Primary Resistance

Aberrant expressions of drug transporters<sup>103-105</sup> and plasma protein binding of TKI<sup>106-108</sup> could contribute to primary resistance by altering the intracellular and plasma concentration of TKI. Monitoring imatinib plasma levels may be useful in determining patient adherence to therapy. However, there are no data to support that change of therapy based on plasma imatinib levels will affect treatment outcomes. Pretreatment levels of organic cation transporter 1 (OCT1) have been reported as the most powerful predictor of response to imatinib.<sup>109</sup> On the other hand, cellular uptake of dasatinib or nilotinib seems to be independent of OCT1 expression, suggesting that patients with low hOCT1 expression might have better outcomes with dasatinib or nilotinib.<sup>110-113</sup>

#### Secondary Resistance

Point mutations in the *BCR-ABL1* kinase domain are the most frequent mechanism of secondary resistance to TKI therapy and are associated

with poor prognosis and higher risk of disease progression.<sup>114-118</sup> Among the BCR-ABL1 kinase domain mutations, T315I mutation confers the complete resistance to imatinib, dasatinib, nilotinib and bosutinib.<sup>119,120</sup> In addition to T315I, F317L and V299L mutants are resistant to dasatinib and Y253H, E255K/V, and F359V/C mutants are resistant to nilotinib.<sup>121-125</sup>

In an analysis of 1043 patients with imatinib-resistant CP-CML, the presence of T315I and F317L mutations at baseline was associated with less favorable responses.<sup>123</sup> Patients with an F317L mutation had a high rate of CHR (93%) but low rates of MCyR and CCyR (14% and 7%, respectively), whereas favorable CCyR rates were achieved in patients with highly imatinib-resistant mutations such as E255K/V (38%) and L248V (40%). A few responses (CHR and MCyR) were observed in patients with T315I mutation but no CCyRs. In another analysis that assessed the occurrence and impact of baseline *BCR-ABL1* mutations on nilotinib therapy in patients with imatinib-resistant CP-CML, 253H, E255V/K, and F359V/C mutations were associated with less favorable MCyR rates (13%, 43%, and 9%, respectively) and none of the patients with these mutations achieved CCyR within 12 months of therapy.<sup>124</sup> E255K/V, F359C/V, Y253H, and T315I mutations were most commonly associated with disease progression and relapse.

Bosutinib has demonstrated activity in patients with BCR-ABL1 mutations resistant to dasatinib (F317L) and nilotinib (Y253H, E255K/V, and F359C/I/V).<sup>126</sup> The most common baseline mutations were T315I, F359C/I/S/V, F317L, G250E, Y253F/H, and M351T. T315I and V299L mutations are resistant to bosutinib. Ponatinib was also active against other *BCR-ABL1* mutations resistant to dasatinib or nilotinib, including E255V, Y253H, and F359V, in addition to T315I.<sup>127</sup>

### **Rising Levels of BCR-ABL1 Transcripts**

Rising levels of *BCR-ABL1* transcripts may be associated with an increased likelihood of detecting BCR-ABL1 mutations and cytogenetic relapse.<sup>128-132</sup> In patients who had achieved very low levels of *BCR-ABL1* transcripts, emergence of BCR-ABL1 mutations was more frequent in those who had more than a 2-fold increase in *BCR-ABL1* levels compared to those with stable or decreasing *BCR-ABL1*.<sup>128</sup> A serial rise has been reported to be more reliable than a single  $\geq 2$ -fold increase in *BCR-ABL1* transcripts.<sup>129,130</sup> Among patients in CCyR with  $\geq 0.5$ -log increase in *BCR-ABL1* transcripts on at least two occasions, those with the highest risk were those who lost MMR with more than 1-log increase in *BCR-ABL1* transcripts had the highest risk of disease progression compared to those who never achieved a MMR and had 1-log increase in *BCR-ABL1* transcripts.<sup>130</sup>

The precise increase in *BCR-ABL1* transcripts that warrants a mutation analysis depends on the performance characteristics of QPCR assay in the laboratory.<sup>132</sup> Some labs have advocated a 2- to 3-fold range,<sup>97,131,132</sup> while others have taken a more conservative approach (0.5-log to 1-log).<sup>130</sup> Obviously, some common sense must prevail, since the amount of change in absolute terms depends on the MMR level. For example, a finding of any *BCR-ABL1* compared to CMR is an infinite increase in *BCR-ABL1* level, though a change from CMR to a barely detectable level is clearly different from a 5-fold increase in a case hovering at the MMR level.

### **Second-Line and Subsequent Therapy (CML-3)**

Based on data demonstrating the prognostic significance of early molecular response at 3 and 6 months, the panel has included  $\leq 10\%$  (1%–10%) *BCR-ABL1* IS as the response milestone at 3 and 6 months.



0.1% to <1% *BCR-ABL1* and <0.1% *BCR-ABL1* are included as response milestones at 12 months and >12 months, respectively.

Continuation of the same dose of TKI therapy (ie, imatinib, dasatinib, nilotinib) and assessment of *BCR-ABL1* transcripts with QPCR (IS) every 3 months is recommended for patients who meet response milestones. If the 3-month response milestone (1%–10% *BCR-ABL1*) is not achieved after first-line TKI therapy, patients are considered to be at high risk for disease progression and should be considered for alternate treatment options. Evaluation for allogeneic HCT (that is, a discussion with a transplant specialist, which might include initiating HLA typing) is recommended if the response milestones are not achieved at 3, 6, and 12 months.

Quite recently, studies have suggested that the rate of decline in *BCR-ABL1* transcripts correlates with longer-term response.<sup>133-136</sup> Among patients with >10% *BCR-ABL1* IS after 3 months of treatment with imatinib, those with a faster decline in *BCR-ABL1* (*BCR-ABL1* halving time < 76 days) had a superior outcome compared to those with a slower decline (4-year PFS rate was 92% vs. 63%, respectively).<sup>133</sup> A rapid initial *BCR-ABL1* decline also identifies a subgroup of Sokal high-risk patients with outcomes similar to those of Sokal low-risk patients.<sup>134</sup> Among Sokal high-risk patients, *BCR-ABL1* halving time of ≤11 days at 1 month was associated with significantly improved FFS (4-year FFS rate was 79% for patients with halving time of ≤11 days at 1 month vs. 53% for those with halving time of > 11 days; *P* = .03). In the German CML IV study, lack of a half-log reduction of *BCR-ABL1* transcripts at 3 months was associated with a higher risk of disease progression on imatinib therapy.<sup>135</sup> The results of the D-First study also showed that in patients treated with dasatinib, *BCR-ABL1* halving time of ≤14 days was a significant predictor of MMR by 12 months and deep molecular response (*BCR-ABL1* <0.01% IS) by 18 months.<sup>136</sup>

The guidelines emphasize that achievement of response milestones months must be interpreted within the clinical context, before making drastic changes to the treatment strategy. Evaluation of compliance to therapy and mutational analysis are recommended prior to changing therapy. Mutational analysis is helpful in the selection of subsequent TKI therapy for patients with inadequate initial response to first-line or second-line TKI therapy.<sup>137</sup> Treatment options based on *BCR-ABL1* mutation status are outlined in [CML-5](#). The guidelines recommend mutational analysis for patients who do not achieve response milestones, any sign of loss of response (hematologic or cytogenetic relapse), and if there is a 1-log increase in *BCR-ABL1* level with loss of MMR. Currently there are no specific guidelines for changing therapy based on rising *BCR-ABL1* levels as detected by QPCR. Changes of therapy based solely on rising *BCR-ABL1* levels should be done only in the context of a clinical trial.

#### **Management of Patients with Inadequate Response to Imatinib**

Dose escalation of imatinib or switching to an alternate TKI is recommended for patients with *BCR-ABL1* transcripts >10% IS after initial treatment with imatinib.

Dose escalation of imatinib up to 800 mg daily has been shown to overcome some of the primary resistance, but the duration of responses has typically been short.<sup>138-141</sup> Dose escalation was particularly effective in patients with cytogenetic relapse who had achieved cytogenetic response with imatinib 400 mg daily.<sup>140</sup> However, it is unlikely to benefit those with hematologic failure or those who never had a cytogenetic response with standard-dose imatinib.

Dasatinib, nilotinib, and bosutinib are active against many of the imatinib-resistant *BCR-ABL1* kinase domain mutants, except T315I,

and are effective second-line and subsequent treatment options for patients intolerant to imatinib or those with resistance.

Dasatinib at different dose levels (70 mg twice daily or 100 mg once daily) has shown equal efficacy in patients with CP-CML intolerant to or resistant to imatinib.<sup>142,143</sup> In the START-R trial, at a minimum follow-up of 2 years, dasatinib (70 mg twice a day) demonstrated higher rates of MCyR (53% vs. 33%), CCyR (44% vs. 18%) and MMR (29% vs. 12%) compared to high-dose imatinib and the estimated PFS also favored dasatinib.<sup>142</sup> In the dose-optimization study (CA180-034) after 7-year follow-up, the MMR, PFS, and OS rates were 46%, 42%, and 65%, respectively for dasatinib 100 mg once daily and the corresponding rates were 46%, 44% and 68% for dasatinib 70 mg twice daily.<sup>143</sup> Severe grade 3 or 4 adverse events including pleural effusion were less frequent with dasatinib 100 mg once daily compared to dasatinib 70 mg twice daily.

In a phase II study, nilotinib (400 mg twice daily) resulted in MCyR and CCyR rates of 59% and 45% respectively, in patients with CP-CML (n = 280) intolerant or resistant to imatinib. The estimated PFS and OS rates at 48 months were 57% and 78%, respectively.<sup>144</sup> The estimated PFS rate at 48 months was higher for patients with CCyR at 12 months (89% compared to 56% for those with no CCyR at 12 months). In the TIDEL-II study, the cohort of patients with >10% *BCR-ABL1* IS at 3 months after imatinib who were switched directly to nilotinib had higher rates of MMR and CMR at 12 months (but not at 24 months) than the cohort of patients who received dose escalation of imatinib before switching to nilotinib.<sup>145</sup>

Bosutinib also has demonstrated activity in patients intolerant to imatinib or in patients with CP-CML resistant to imatinib. In a phase I-II study of 288 patients (196 patients with CP-CML resistant to imatinib

and 90 patients intolerant to imatinib), after a median follow-up of 44 months, bosutinib resulted in MCyR and CCyR rates of 59%, and 49%, respectively.<sup>146</sup> The estimated 2-year OS rate was 88% for patients with resistance to imatinib and 98% for patients with intolerance to imatinib. At 4 years, the cumulative incidence of disease progression to AP-CML or BP-CML was 22% for patients with resistance to imatinib and 10% for patients with intolerance to imatinib. Diarrhea (86%), nausea (46%), rash (36%) and vomiting (37%) were the most common adverse events.

### **Management of Patients with Inadequate Response to Dasatinib or Nilotinib**

Although failure to achieve  $\leq 10\%$  *BCR-ABL1* IS at 3 months after first-line therapy with dasatinib or nilotinib is associated with a high risk for disease progression, there is no clear evidence to support that switching to alternate TKI therapy would improve long-term clinical outcome for this group of patients. Some investigators have suggested that response assessment at 3 months has a superior prognostic value over response assessment at 6 months.<sup>93</sup> In a more recent report, Marin and colleagues established the superior prognostic value of molecular response assessment at 3 months over molecular response assessment at 6 months.<sup>93</sup> The 8-year probability of OS for those with low *BCR-ABL1* transcripts at 3 months and high *BCR-ABL1* transcripts at 6 months following imatinib therapy was similar to that of patients who had low *BCR-ABL1* transcripts at both time points (92.4% and 93.5%, respectively;  $P = .78$ ). However, others have reported that assessment of response at 6 months may provide a better predictor for long-term outcome.<sup>147</sup> In an analysis of 456 patients with CP-CML treated with first-line TKI therapy (imatinib, dasatinib, or nilotinib), patients with >10% *BCR-ABL1* IS at 3 months who subsequently achieved <10% *BCR-ABL1* IS at 6 months had survival outcomes very similar to that of patients who initially achieved <10% *BCR-ABL1* IS) at

3 months. At a median follow-up of 95 months, the 5-year OS rates were 100% and 93% respectively.<sup>147</sup> The 5-year OS rate is significantly lower (81%) for patients with >10% *BCR-ABL1* IS at 3 and 6 months.

Patients with *BCR-ABL* only slightly >10% at 3 months and/or with a steep decline from baseline, may achieve <10% at 6 months and have generally favorable outcomes. Therefore, it is important to interpret the value at 3 months in this context, before making drastic changes to the treatment strategy. Patients with >50% reduction in *BCR-ABL1* compared to baseline or minimally >10% *BCR-ABL1* can continue the same dose of dasatinib or nilotinib for another 3 months, if response milestones are not achieved at 3 months after first-line dasatinib or nilotinib. Patients with intolerance to first-line dasatinib or nilotinib or those with disease that is resistant to dasatinib or nilotinib could be treated with an alternate TKI (other than imatinib) in the second-line setting.

Bosutinib is an effective treatment option for patients with CP-CML pretreated with dasatinib or nilotinib. In the cohort of 119 patients with CP-CML pretreated with more than one TKI (imatinib followed by dasatinib and/or nilotinib), at 40 months of follow-up, CHR, MCyR, and estimated 4-year OS rates were 74%, 40%, 32%, and 78%, respectively.<sup>148</sup> Diarrhea (83%), nausea (48%), vomiting (38%), and thrombocytopenia (39%) were the most common adverse events.

Ponatinib is an option for patients with T315I mutation and for those with disease that has not responded to multiple TKIs. In the PACE trial, after the median follow-up was 37 months, in the cohort of 267 patients with CP-CML refractory  $\geq 3$  prior TKIs or those with T315I mutation (51% of patients had disease that is resistant to prior TKI or intolerant dasatinib or nilotinib and 70% of patients had T315I mutation), ponatinib induced durable MCyR, CCyR, MMR, and MR4.5

in 59%, 54%, 39%, and 23% of patients, respectively.<sup>149</sup> Among patients who achieved MCyR and MMR, responses were durable for 82% and 61% of patients, respectively. The estimated 4-year PFS and OS rates were 56% and 77%, respectively. In a post hoc analysis, exposure to fewer prior TKIs and shorter duration of leukemia were identified as predictors of response.<sup>150</sup> Response rates were higher in patients who were exposed to fewer prior TKIs (MCyR, CCyR, and MMR rates were 84%, 79%, and 53%, respectively, for patients treated with one prior TKI compared to 46%, 38%, and 29%, respectively, for those treated with 3 prior TKIs).

Hepatotoxicity, liver failure, and death have been rarely reported in patients treated with ponatinib. Liver function tests should be done at baseline, and at least monthly or as clinically indicated during treatment. Dose interruption and dose reductions or discontinuation of ponatinib should be considered for hepatotoxicity. Serious arterial and venous thrombosis and occlusions occurred in approximately 27% of patients: cardiovascular occlusion, cerebrovascular occlusion, and peripheral arterial occlusive events occurred in 12%, 6%, and 8% of patients, respectively. Heart failure, including fatalities, occurred in 8% of patients.<sup>151</sup> These adverse events were seen in patients with and without cardiovascular risk factors (such as history of ischemia, hypertension, diabetes, or hyperlipidemia). Ponatinib labeling contains a black box warning regarding vascular occlusion, heart failure, and hepatotoxicity. Cardiovascular risk factors (eg, diabetes mellitus, hypertension, hyperlipidemia, smoking, estrogen use) should be identified and controlled before starting ponatinib. Patients should be monitored for evidence of thromboembolism and vascular occlusion. Ponatinib should be interrupted or stopped immediately for vascular occlusion and for new or worsening heart failure. Patients with cardiovascular risk factors should be referred to a cardiologist.

Ponatinib is now indicated only for the treatment of patients with T315I mutation and for the treatment of patients for whom no other TKI therapy is indicated in all phases of CML. The recommended initial dose of ponatinib is 45 mg once daily. Dose intensity of ponatinib is significantly associated with increased risk of adverse events.<sup>152</sup> Therefore, dose modifications may be necessary for the management of adverse events. In a post hoc analysis that assessed the clinical impact of dose modification and dose intensity on outcomes of patients treated with ponatinib in the PACE trial, dose intensity was also the most significant predictor of MCyR by 12 months.<sup>153</sup> However substantial responses were observed at lower dose levels. The estimated MCyR rates were approximately 75% at 45 mg, 60% at 30 mg, and 30% at 15 mg. Thus, an initial dose of 30 mg may be a safer and effective dose for patients with cardiovascular risk factors. Safety and efficacy of ponatinib at initial doses lower than 45 mg are being evaluated in a randomized clinical trial.

Omacetaxine has demonstrated safety and efficacy in patients with T315I mutation and in those with CML that is resistant to  $\geq 2$  TKIs.<sup>154-156</sup> In a phase II study (CML 202 study), among 62 evaluable patients with T315I mutation and CP-CML resistant to prior TKI therapy, CHR, MCyR, and CCyR were seen in 77%, 23%, and 16% of patients, respectively.<sup>154</sup> MMR was achieved in 17% of patients and the T315I clone declined to below detection limits in 61% of patients. Median duration of CHR and MCyR was 9 and 7 months, respectively. After a median follow-up of 19 months, median PFS was 7.7 months and the median OS had not yet been reached. In the cohort of 46 patients with CP-CML that is resistant to  $\geq 2$  TKIs (CML 203 study), hematologic response was achieved or maintained in 67% of patients, with median response duration of 7.0 months; MCyR and CCyR were achieved in 22% and 4% of patients, respectively. Median PFS and OS were 7.0

months and 30 months, respectively.<sup>155</sup> Omacetaxine had an acceptable toxicity profile and the most common grade 3/4 adverse events were thrombocytopenia (67%), neutropenia (47%), and anemia (37%).<sup>156</sup>

### Response Milestones after Second-Line TKI Therapy

Early cytogenetic response or molecular response to second-line and subsequent TKI therapy has been reported to be a predictor of OS and PFS. Achievement of cytogenetic response and early molecular response to second-line dasatinib was associated with improved PFS and OS.<sup>143,157</sup> The estimated rates 7-year PFS, OS and transformation-free survival rates were 56%, 72% and 93% respectively for patients with  $\leq 10\%$  *BCR-ABL1* at 3 months compared to 21%, 56% and 88% respectively for those with  $>10\%$  *BCR-ABL1* at 3 months.<sup>143</sup> The estimated 6-year rates of transformation-free survival were 87% and 89% respectively for patients who achieved CCyR or PCyR at 3 months compared to 65% for those who achieved neither at 3 months.<sup>157</sup> The corresponding OS rates were 88%, 90% and 61% for patients who achieved CCyR, PCyR or neither at 6 months. The achievement of early molecular response to second-line nilotinib at 12 months was associated with higher PFS rates at 48 months in patients with CP-CML (n = 280) intolerant of or resistant to imatinib.<sup>144</sup> The estimated PFS rates at 48 months were 85% for patients with  $\leq 1\%$  *BCR-ABL1* at 3 months compared to 67% and 42% respectively for those with  $>1\%$  to  $10\%$  *BCR-ABL1* and  $>10\%$  *BCR-ABL1* at 3 months. Landmark analyses of the PACE trial also showed that greater reductions in *BCR-ABL1* transcript levels at 3, 6, and 12 months after treatment with ponatinib were associated with improved PFS and OS at 3 years.<sup>158</sup>

Based on the available data, patients who do not achieve cytogenetic or molecular responses at 3, 6, or 12 months after second-line and subsequent TKI therapy should be considered for alternative therapies or allogeneic HCT if deemed eligible. The use of an alternate TKI after treatment failure with two prior TKIs is not associated with durable responses, except in occasional patients in chronic phase.<sup>159</sup> Mutational analysis may identify a subgroup of patients who require careful monitoring (as these patients are at a higher risk of progression) and the subset of patients who will be eligible for allogeneic HCT.

### Discontinuation of TKI Therapy

TKI therapy has significantly reduced the annual mortality rate among patients with CML and it is the standard first-line therapy for patients with newly diagnosed CP-CML. In the majority of patients achieving CCyR, CML is now managed like a chronic disease, requiring long-term treatment and supportive care. However, majority of patients who achieve a clinically undetectable level of *BCR-ABL1* transcripts by the most sensitive QPCR assay continue to harbor minimal residual disease that may eventually lead to disease recurrence. Several clinical studies have evaluated the feasibility of discontinuation of TKI therapy (with close monitoring) in carefully selected patients who have achieved and maintained deep molecular response ( $\geq$ MR 4.0;  $\leq$ 0.01% *BCR-ABL1* IS) for 2 or more years.<sup>160-172</sup>

The possibility of treatment-free remission (TFR) after discontinuation of imatinib was first evaluated in the Stop Imatinib (STIM) study in 100 patients with a CMR for at least 2 years (5-log reduction in *BCR-ABL1* levels and undetectable minimal residual disease on QPCR with a sensitivity of  $\geq$ 4.5-log reduction from the standardized baseline).<sup>160,161</sup> At the median follow-up of 65 months, the probabilities of relapse-free survival and treatment-free survival were 38% and 41%, respectively, at

24 months after discontinuation of imatinib.<sup>161</sup> Other subsequent TKI discontinuation trials have also reported similar findings.<sup>162-172</sup> Limited longer-term follow-up data from the TKI discontinuation trials are summarized in [Table 1](#).<sup>173</sup>

Approximately 40% to 60% of patients who have discontinued TKI therapy after achieving deep molecular remission usually have a recurrence within 6 months of treatment cessation, in some cases as early as one month after discontinuation of TKI therapy. In the STIM study, molecular relapse (trigger to resume TKI therapy) was defined as positivity for *BCR-ABL1* transcripts by QPCR confirmed by a 1-log increase in *BCR-ABL1* transcripts between two successive assessments or loss of MMR at one point.<sup>160,161</sup> The results of the A-STIM study showed the loss of MMR ( $\leq$ 0.1% *BCR-ABL1* IS) could be used as a practical criterion for restarting therapy since the estimated probability of losing MMR at 24 months after discontinuation of imatinib was lower than the probability of losing CMR (36% compared to 54%).<sup>165</sup> Resumption of TKI therapy immediately after recurrence results in the achievement of undetectable minimal residual disease in almost all patients.<sup>160-172</sup>

Some patients may experience significant adverse events that are believed to be due to TKI discontinuation. An imatinib withdrawal syndrome (aggravation or new development of musculoskeletal pain and/or pruritus after discontinuation of imatinib) was reported in 30% patients in the KIDs study and the occurrence of imatinib withdrawal syndrome was associated with a lower rate of molecular relapse.<sup>167</sup> ENESTFreedom and ENESTop studies also reported musculoskeletal pain during the TFR period in 25% and 42% of patients, respectively.<sup>170,171</sup>





Several factors may help predict relapse after discontinuation of TKI therapy (eg a higher Sokal risk score, female gender, natural killer (NK) and T-cell counts, suboptimal response or resistance to imatinib, duration of TKI therapy and deep molecular response prior to TKI discontinuation).<sup>160,161,166,168,169,172</sup> However, only the duration of TKI therapy and deep molecular response prior to TKI discontinuation therapy have been associated with TFR with a high level of consistency.<sup>160,169,172</sup>

Based on the available evidence from clinical studies that have evaluated the feasibility of TFR, the panel members feel that discontinuation of TKI therapy (with *close monitoring*) is feasible in carefully selected patients (in early CP-CML with no history of resistance to TKI therapy) who have achieved and maintained a deep molecular response ( $\geq$ MR4) for  $\geq$ 2 years. Clinical studies that have evaluated the safety and efficacy of TKI discontinuation have employed strict eligibility criteria and have mandated more frequent molecular monitoring than typically recommended for patients on TKI therapy. Access to a reliable QPCR (IS) with a sensitivity of detection of  $\geq$ 4.5 log reduction and the availability of test results within 2 weeks is one of the key requirements to monitor patients after TKI discontinuation and ascertain their safety. The criteria for the selection of patients suitable for discontinuation of TKI therapy are outlined in [CML-F](#). The guidelines emphasize that discontinuation of TKI therapy outside of a clinical trial should be considered only if ALL of the criteria included in the list are met.

## Management of Advanced Phase CML (CML-4)

### TKI Therapy

Imatinib has induced favorable hematologic and cytogenetic response rates in patients with AP-CML or BP-CML.<sup>174-179</sup> Dasatinib,<sup>180,181</sup>

nilotinib,<sup>182,183</sup> bosutinib,<sup>184</sup> and ponatinib<sup>185</sup> have demonstrated activity in imatinib-resistant or imatinib-intolerant AP-CML or BP-CML.

Dasatinib 140 mg once daily has similar efficacy to 70 mg twice-daily dosing with an improved safety profile in patients with AP-CML and BP-CML.<sup>180,181</sup> In a phase III study of 317 patients with AP-CML randomized to 140 mg once daily (n = 158) or 70 mg twice-daily (n = 159), the rates of MCyR and the estimated PFS and OS rates at 24 months were comparable in the 2 treatment groups (MCyR, 39% vs. 43%; PFS, 51% vs. 55%; OS, 63% vs. 72%).<sup>180</sup> In a phase III study of patients with BP-CML, dasatinib 140 mg once daily and 70 mg twice-daily resulted in similar rates of MCyR (25% vs. 28%) and OS rates at 24 months (24% vs. 28%) in patients with myeloid BP-CML.<sup>181</sup> In patients with lymphoid BP-CML, dasatinib 140 mg once daily resulted in higher rates of MCyR compared to 70 mg twice daily (50% vs. 40%), and the OS rates at 24 months were 21% and 16%, respectively. In patients with imatinib-resistant or imatinib-intolerant AP-CML, after a median 24 months of follow-up (n = 137), nilotinib resulted in MCyR and CCyR in 32% and 20% of patients, respectively.<sup>182</sup> The durability of MCyR and CCyR were 66% at 24 months and 83% at 12 months, respectively. The estimated PFS and OS rates at 24 months were 70% and 33%, respectively. In a phase II study of 136 patients (MBC, n = 105; LBC, n = 31), after a minimum follow-up of 24 months, MCyR was achieved in 38% of patients with MBC and 52% of patients with LBC.<sup>183</sup> CCyR was seen in 30% of patients with MBC and 32% of patients with LBC. The OS rate was 42% at 12 months and 27% at 24 months. The duration of MCyR was 11 months for patients with MBC and 3 months for those with LBC.

Long-term efficacy and safety data ( $\geq$ 4 years of follow-up) showed that bosutinib induces hematologic response and MCyR in patients with advanced-phase CML with and without *BCR-ABL1* mutations.<sup>184</sup> In the

cohort of patients with AP-CML ( $n = 79$ ), MCyR was attained or maintained in 40% of patients.<sup>184</sup> Among patients with BP-CML ( $n = 64$ ), the corresponding response rates in patients with BP-CML evaluable for response were 28% and 37%, respectively. Responses were durable in approximately 50% of patients with AP-CML at 4 years; approximately 25% of patients with BP-CML responded at one year.

The PACE trial confirmed the efficacy of ponatinib in patients with advanced phase CML intolerant to  $\geq 3$  TKIs or those with resistant disease.<sup>185</sup> After a median follow-up of 28 months, MaHR and 2-year OS rates were 62% and 72%, respectively, for patients with AP-CML. The corresponding MaHR and 2-year OS rates were 32% and 18%, respectively, for patients with BP-CML. Among patients with T315I mutation, MaHR rates were 61%, and 29%, respectively, for patients with AP-CML and BP-CML.

The efficacy of imatinib in combination with decitabine or cytarabine-based chemotherapy in AP-CML and myeloid BP-CML has been demonstrated in several small studies.<sup>186-189</sup> Hyper-CVAD in combination with imatinib or dasatinib is also effective for patients with lymphoid BP-CML, particularly when followed by allogeneic HCT.<sup>190,191</sup> Among 42 patients with BP-CML, CCyR and CMR were achieved in 58% and 25% of patients, respectively. The median remission duration and median OS were 14 months and 17 months, respectively. In multivariate analysis, the median remission duration was longer among HCT recipients ( $P = .01$ ); the median OS was longer among HCT recipients ( $P < .001$ ) and in patients treated with dasatinib ( $P = .07$ ).<sup>191</sup>

Omacetaxine is a feasible treatment option for advanced phase CML that is resistant to multiple TKIs as well as for patients with T315I mutation.<sup>192</sup> Among the 51 patients with AP-CML, after a median follow-up of 16 months, MaHR, CHR, and minor cytogenetic response

were achieved or maintained in 37%, 29%, and 11% of patients, respectively.<sup>192</sup> MaHR rates were 55% and 58%, respectively, for patients with a history of T315I mutation and for those with confirmed T315I mutation at baseline. The median PFS and OS were 4.8 months and 17.6 months, respectively. The most common grade 3/4 hematologic adverse events were thrombocytopenia (51%), anemia (39%), neutropenia (20%), and febrile neutropenia (14%).

### Allogeneic Hematopoietic Cell Transplant

Allogeneic HCT is a potentially curative treatment for patients with CML, but the excellent results with TKI therapy have challenged the role of allogeneic HCT as a first-line therapy for patients with CP-CML. Allogeneic HCT is no longer recommended as a first-line treatment option for CP-CML. Allogeneic HCT is an appropriate first-line treatment option for the very rare patients presenting with blast phase at diagnosis, patients with T315I and other BCR-ABL1 mutations that are resistant to all TKIs, and for the rare patients intolerant to all TKIs.<sup>193-196</sup>

Ongoing advances in alternative donor sources (such as unrelated donors and cord blood), more accurate HLA typing for a stringent selection of unrelated matched donors,<sup>197,198</sup> and the use of reduced-intensity conditioning regimens<sup>199-203</sup> have improved outcomes following allogeneic HCT. Several studies have confirmed that TKI therapy prior to allogeneic HCT does not compromise the outcome following allogeneic HCT or increase transplant-related toxicity.<sup>204-210</sup>

Disease phase, HLA matching, age and sex of the donor and recipient, and time from diagnosis to transplant have been identified as pretransplant risk factors.<sup>211</sup> Low HCT comorbidity index has been identified as prognostic indicators of lower non-relapsed mortality rate and a somewhat improved survival rate.<sup>212</sup> The disease phase at the

time of transplant remains an important prognostic factor and the survival outcomes following transplant are clearly better for patients in CP-CML compared to patients with AP-CML or BP-CML.<sup>213-218</sup>

Therefore, the potential use of transplantation must be tied to faithful monitoring of disease, since the major potential pitfall in delaying transplantation is “missing” the chronic phase interval.

### Treatment Considerations

Participation in clinical trials (evaluating TKI in combination with chemotherapy or other novel treatment options) is recommended for all patients with AP-CML or BP-CML. Treatment options are based on patient’s age and comorbidities. Disease progression to advanced phase while on TKI therapy has worse prognosis than de novo advanced phase CML. In patients with disease progression to AP-CML or BP-CML, the selection of TKI therapy is based on prior therapy and/or mutational analysis. Mutational analysis is recommended for all patients with AP-CML and BP-CML prior to initiation of TKI therapy. A significant portion of patients with AP-CML or BP-CML treated with TKI therapy achieve a MCyR but not a concomitant CHR because of persistent cytopenias and because the absence of a CHR at the time of MCyR was associated with an inferior outcome.<sup>219</sup> The role of allogeneic HCT should be discussed based on response to therapy.

#### Accelerated phase CML

TKI therapy is recommended as first-line treatment for patients with newly diagnosed AP-CML. Allogeneic HCT can be considered based on response to TKI therapy. In patients with disease progression to AP-CML on prior TKI therapy, treatment with a course of alternate TKI (not received before) will be beneficial as a “bridge” to allogeneic HCT. Omacetaxine is an option for patients with disease progression to AP-CML on TKI therapy.<sup>192</sup>

#### Blast Phase CML

Allogeneic HCT is an appropriate first-line treatment option for the very rare patients presenting with BP-CML at diagnosis. In patients with disease progression to BP-CML on prior TKI therapy, treatment with a course of alternate TKI (not received before) will be beneficial as a “bridge” to allogeneic HCT. TKI therapy in combination with chemotherapy or steroids is recommended for patients with myeloid or lymphoid BP-CML. ALL-type chemotherapy is recommended for patients with lymphoid BP-CML and AML-type chemotherapy is recommended for those with myeloid BP-CML.

Central nervous system (CNS) involvement has been described in case reports of BP-CML.<sup>220-223</sup> Lumbar puncture and CNS prophylaxis is recommended for lymphoid blast phase. Documented CNS involvement in patients with lymphoid BP-CML should be managed according to the standard of care for AML or ALL. TKI therapy has not been optimized for patients with CNS involvement. Dasatinib has been reported to cross the blood brain barrier and may represent the best TKI option for patients with CNS disease.<sup>224</sup>

#### Monitoring Response after Allogeneic HCT (CML-6)

*BCR-ABL1* transcripts may persist after many years in most patients after allogeneic HCT. The prognostic significance of *BCR-ABL1* positivity is influenced by the time of testing after allogeneic HCT. While a QPCR assay positive for *BCR-ABL1* at 6 to 12 months after transplant is associated with a high risk of relapse, a positive QPCR assay at a much later time point after transplant is associated with a lower risk of relapse.<sup>225-232</sup> Early detection of *BCR-ABL1* transcripts after transplant may be useful to identify patients who may be in need of alternative therapies before the onset of a complete relapse.

### Management of Post-transplant Relapse (CML-6)

Donor lymphocyte infusion (DLI) is effective in inducing durable molecular remissions in the majority of patients with relapsed CML following allogeneic HCT, though it is more effective in patients with chronic phase relapse than advanced phase relapse.<sup>233-238</sup> However, DLI is associated with complications such as graft-vs-host disease (GVHD), susceptibility to infections, and immunosuppression.<sup>233</sup> Improvements in the methods of detecting *BCR-ABL1* transcripts to predict relapse, the development of reduced-intensity conditioning regimens, modified delivery of lymphocytes with the depletion of CD8+ cells, and the use of escalating cell dosage regimens have reduced the incidence of GVHD associated with DLI.<sup>239-243</sup>

Imatinib is very effective in inducing durable cytogenetic and molecular responses in the majority of patients relapsing with chronic and advanced phase CML following allogeneic HCT, and the response rates are higher in patients with chronic phase relapse than advanced phase relapse.<sup>244-251</sup> Very limited data are available on the use of dasatinib and nilotinib in a small number of patients with post-transplant relapse.<sup>252-258</sup> Imatinib is also effective in the prophylactic setting to prevent relapse following HCT in high-risk patients.<sup>259,260</sup>

There are also data suggesting that the use of DLI in combination with imatinib may be more effective at inducing rapid molecular remissions than either modality alone.<sup>261</sup> Recent retrospective studies have shown that TKIs are better than DLI alone or in combination with TKI for post-transplant relapse.<sup>262,263</sup> However, these observations are yet to be confirmed in randomized trials.

Patients who are in CCyR (QPCR-negative) should undergo regular QPCR monitoring (every 3 months for 2 years, then every 3–6 months thereafter). Given the high risk for hematologic relapse in patients with

prior accelerated or blast phase, post-transplant TKI therapy should be considered for at least one year in this cohort of patients who are in remission following allogeneic HCT.<sup>259,260</sup>

TKI with or without DLI or omacetaxine can be considered for patients who are not in remission or in cytogenetic relapse or those with an increasing level of molecular relapse. The selection of TKI depends on prior TKI, agent's side effect profile, the presence of comorbidities, and mutational status. Pre-existing mutations in the ABL kinase domain, frequently associated with resistance to TKIs are persistently detectable in the majority of patients who relapse after allogeneic HCT.<sup>264</sup> Mutational analysis is therefore essential prior to the selection of TKI for the treatment of post-transplant relapse.

In patients with CML that has previously failed imatinib, there are no data to support the use of post-transplant imatinib. Dasatinib, nilotinib, bosutinib, ponatinib, or omacetaxine may be more appropriate for patients with CML that has previously failed imatinib. However, there are no data to support the use of post-transplant bosutinib, ponatinib, or omacetaxine. CNS relapse of CML following allogeneic HCT has been described in few case reports.<sup>265,266</sup> Dasatinib may also be an effective treatment for extramedullary relapse following allogeneic HCT.<sup>224,267,268</sup> Participation in a clinical trial should be encouraged.

### Management of CML During Pregnancy

The median age of disease onset is 67 years, but CML occurs in all age groups. The EUTOS population-based registry has reported that approximately 36.5% of patients at the time of diagnosis are of reproductive age.<sup>269</sup> Clinical care teams should be prepared to address issues relating to fertility and pregnancy as well as counsel these patients about the potential risks and benefits of treatment discontinuation and possible resumption of TKI therapy should CML

recur during pregnancy. Referral to a CML specialty center is recommended.

### TKI Therapy and Conception

Imatinib, dasatinib, and nilotinib have been shown to be teratogenic and are known to cause embryonic or fetal toxicities in animal studies. TKI therapy appears to affect some male hormones at least transiently, but these drugs do not appear to have an effect on fertility in men, nor is the miscarriage or fetal abnormality rate higher in female partners of men on TKI therapy.<sup>270-274</sup> The situation is more complex for women as TKI therapy during pregnancy has been associated with both a higher rate of miscarriage and fetal abnormalities.<sup>275,276</sup> Pye and colleagues reported the outcome of pregnancies in 180 women exposed to imatinib during pregnancy. Fifty percent of pregnancies with known outcome were normal and 10% of pregnancies with known outcome had fetal abnormalities.<sup>275</sup> Eighteen pregnancies ended in spontaneous abortion. Cortes and colleagues reported the outcomes of pregnancy and conception during treatment with dasatinib.<sup>276</sup> Among 46 women treated with dasatinib, 15 women (33%) delivered a normal infant. Elective or spontaneous abortions were reported in 18 women (39%) and 8 women (17%), respectively, and 5 women (11%) had an abnormal pregnancy. Fetal abnormalities were reported in 7 cases. Among 33 women fathered by dasatinib-treated men, 30 women (91%) delivered infants who were normal at birth. Although there are no data regarding the outcome of pregnancy in patients receiving bosutinib and ponatinib at the time of conception, these agents must be considered unsafe to use in pregnant women.

Discontinuation of TKI therapy because of pregnancy in women who were not in a CMR has only been reported in two small series.<sup>277,278</sup> Ault and colleagues have reported 10 women who stopped imatinib

because of pregnancy after a median of 8 months of therapy.<sup>277</sup> Five of the nine women who had achieved a CHR lost the response after stopping therapy, and six had an increase in Ph-positive metaphases. At 18 months after resuming therapy, all nine patients had achieved a CHR but only three women achieved a CCyR and none had achieved an MMR. Kuwabara and colleagues reported outcomes of seven women who were not in a CMR at the time imatinib was stopped because of pregnancy, three of whom were in an MMR.<sup>278</sup> All seven women had disease progression. The three women who had an MMR at the time imatinib was stopped were able to regain the same response once the drug was restarted, whereas the remaining four patients were not.

Depending on other factors such as age, a natural pregnancy may occur months after stopping TKI therapy. Assuming the earliest time a woman could conceive and give birth naturally, without any wash out period, is 10 months after stopping her TKI, the likelihood is in the range of 60% that her PCR will become positive if she was in a CMR when she became pregnant; it is even higher if she was not in a CMR when she became pregnant.<sup>277,278</sup>

### Planning a Pregnancy

Prior to attempting pregnancy, women and their partners should be counseled that no guidelines exist regarding how best to monitor CML during pregnancy, nor how best to manage progressive disease should it occur during pregnancy. Conception while on active TKI therapy is strongly discouraged due to the risk of fetal abnormalities.

TKI therapy does not appear to have a deleterious effect on male sperm and the general recommendation is that men who take TKIs do not need to stop therapy if a pregnancy is planned, although experience is limited. Sperm banking can also be performed prior to starting TKI

therapy, although there are no data regarding quality of sperm in untreated men with CML.

In women, due to the risk of miscarriage and fetal abnormalities during pregnancy, TKI therapy should be stopped prior to natural conception and the patient should remain off therapy during pregnancy.<sup>275,276</sup> Consultation with a high-risk obstetrician is recommended. Referral to an IVF center is recommended and in coordination with the patient's obstetrician, TKI therapy should be stopped prior to oocyte retrieval. It is not known how long TKI should be stopped prior to attempting a natural pregnancy or oocyte retrieval. Compounding the high incidence of disease recurrence off TKI therapy are the significant obstacles that exist for women who choose one of the above forms of IVF, chief among which is the lack of access to centers that perform the procedure, high costs associated with the drugs and surgical procedures that may not be covered by insurance, costs of embryo/oocyte storage, and access to surrogate programs. Some women may require more than one IVF cycle to obtain enough potentially viable embryos for implantation. In addition, women may need a family medical leave from work to attend IVF appointments. It is also important to note that not all states allow surrogacy.

TKI therapy can be restarted after the baby is born. Women on TKI therapy should also be advised not to breast feed, as TKIs pass into human breast milk.<sup>279,280</sup> If TKI therapy should be provided during pregnancy, the potential benefit for the mother and the potential risk to the fetus of continuing TKI therapy vs. the risk of treatment interruption leading to the loss of optimal disease response must be carefully evaluated on an individual basis prior to initiation of TKI therapy. Fertility preservation should be discussed with all patients of childbearing age prior to the initiation of TKI therapy.

### Monitoring and Treatment During Pregnancy

It is recommended to check monthly peripheral blood QPCR, and initiate treatment if the *BCR-ABL1* increases to >1.0% IS. Most of the literature regarding treatment during pregnancy consists of case reports. Leukapheresis can be initiated for a rising WBC, although there are no data that recommend at what level WBC this should be started.<sup>281-283</sup> Low-dose aspirin or low-molecular-weight heparin can also be considered for patients with thrombocytosis.<sup>284,285</sup> Interferon alpha (in wide range of doses: 3–6 million units every other day to 5–8 million units daily) has been shown to be safe during pregnancy, although it has a low rate of molecular response.<sup>282,286-289</sup> Hydroxyurea (in wide range of doses) is also considered safe during pregnancy.<sup>282,290-292</sup> The potential risk and benefit balance should be carefully evaluated in terms of maternal health and fetal risk prior to initiation of treatment during pregnancy, especially during the first trimester.

### Specific Considerations for Children with CML

CML accounts for less than 3% of all pediatric leukemias. In general, children are diagnosed at a median age of 11 to 12 years, with approximately 10% presenting in advanced phase. As a consequence of its rarity, there are no evidence-based recommendations for the management of CML in the pediatric population. Many pediatric oncologists follow treatment guidelines that are designed for adult patients. However, clinical presentations and host factors are different between children and adults, and some factors should be considered when treating pediatric patients with CML.<sup>293-295</sup>

### Selection of TKI

Imatinib has been evaluated in pediatric patients with newly diagnosed chronic phase CML in clinical studies.<sup>296-298</sup> It is the only TKI that is

currently approved as first-line treatment for children with CML by the U.S. Food and Drug Administration. In the French National phase IV study, 44 patients from age 10 months to 17 years with newly diagnosed chronic phase CML were treated with imatinib (260 mg/m<sup>2</sup>).<sup>297</sup> At a median follow-up of 31 months, a CHR was achieved in 98% of the patients and the estimated PFS rate at 36 months was 98%. At 12 months, the rates of CCyR and MMR were 61% and 31%, respectively. The updated results of this trial showed that early molecular response at 3 months ( $\leq 10\%$  *BCR-ABL1* IS) correlated with better PFS and higher rates of CCyR and MMR at 12 months.<sup>298</sup>

Higher dose imatinib (340 mg/m<sup>2</sup>) has also been shown to be effective and well tolerated in children, inducing a high rate of hematologic, cytogenetic, and molecular responses.<sup>299,300</sup> Long-term results of an Italian multicenter study (47 patients with chronic phase CML) showed that higher dose imatinib (340 mg/m<sup>2</sup>) induced CCyR in 91.5% of the evaluable patients at a median time of 6 months.<sup>300</sup> At 12 months, MMR ( $\leq 0.1\%$  *BCR-ABL1*) and MR ( $\leq 0.01\%$  *BCR-ABL1*) were observed in 66.6% and 33% of patients, respectively. Imatinib has also been effective in children with late chronic phase and advanced phase CML as well as for disease relapse following allogeneic HCT.<sup>301</sup>

Dasatinib has been evaluated in phase I/II studies in the pediatric population with relapsed or refractory CML.<sup>302,303</sup> In a dose escalation study that evaluated dasatinib (60 mg/m<sup>2</sup> to 120 mg/m<sup>2</sup>) in 58 children with relapsed or refractory leukemia, CCyR and MMR were achieved in 82% and 47% of patients with imatinib pretreated chronic phase CML.<sup>303</sup> After 24 months of follow-up, median CHR and MCyR durations were not reached. Nilotinib has also been evaluated in a small series of pediatric patients with CML refractory to prior TKI therapy.<sup>304</sup> The efficacy and safety of nilotinib in pediatric patients with newly diagnosed CML is being evaluated in an ongoing phase II trial. Bosutinib and

ponatinib<sup>305</sup> have not been tested in children in clinical trials; therefore, there is little information on the safety of these drugs in children.

The validity of prognostic scores (eg, Sokal, Hasford, and EUTOS scores) has not been established in the pediatric population. In an analysis that attempted to validate the three prognostic scoring systems in a cohort of 90 children (median age 12 years), there was a high discordance among the scoring methods.<sup>306</sup> Therefore, it is not recommended to use these scoring systems for risk assessment or to make treatment decisions for children with CML.

### Monitoring for Long-Term Side Effects

Children have a much longer life expectancy than adults and TKI therapy may be needed for many decades; therefore, there is potential long-term morbidity that may not be seen in adults. There are no data available on the cessation of TKI therapy in the pediatric population and discontinuation of TKI therapy in children is not recommended outside the context of a clinical trial.<sup>307</sup>

A number of studies have reported impaired longitudinal growth in children with CML treated with TKIs.<sup>308-316</sup> It appears that prepubertal children are affected more significantly.<sup>313,316,317</sup> Growth should be monitored closely and a bone age x-ray should be obtained if longitudinal growth is delayed. A DEXA scan should be obtained if bone mineral density is decreased on plain radiograph or if there is unprovoked fracture. Further evaluation and referral to an endocrinologist is also warranted.

### Immunizations

There are little data on immune function with patients on TKI therapy, and it potentially hinders routine vaccination for children with CML.<sup>318</sup> In general, administration of inactivated killed vaccines to children on TKI



## NCCN Guidelines Version 1.2018 Chronic Myeloid Leukemia

therapy is safe, although response may be insufficient as in any immunocompromised patient. A study showed a higher seroconversion rate to H1N1 influenza vaccine in adult CML patients compared to patients with B-cell malignancies or HCT recipients.<sup>319</sup> Administration of live vaccines during TKI therapy is not recommended in general, although one study showed that varicella vaccine could be safely given to some children with immune deficiency.<sup>320</sup> Live vaccines could be considered after stopping TKI therapy for several weeks in patients with a deep molecular response. In the United States, all required live vaccines are completed by the age of 4 to 6 years (<http://www.cdc.gov/vaccines/>). As CML is rarely seen in children younger than this age, few patients face this issue. For the annual influenza vaccine, the live attenuated vaccine (nasal spray) should be avoided, and the inactivated killed vaccine (flu shot) should be used for children receiving TKI.

Discussion  
update in  
progress




**Table 1. Summary of Limited Longer-term Follow-up Data from the TKI Discontinuation Trials**

Study	Treatment prior to discontinuation	No. of patients	Depth and duration of molecular response (MR) required for discontinuation	Trigger to resume TKI therapy	Median duration of follow-up	Treatment-free remission (TFR) rate
STIM <sup>160,161</sup>	Imatinib ± interferon	100	MR5.0 for at least 2 years	Loss of MR5.0	65 months	41% at 24 months
STIM2 <sup>162</sup>	Imatinib	124	MR5.0 for at least 2 years	Loss of MR5.0	12 months	61% at 12 months
TWISTER <sup>163</sup>	Imatinib ± interferon	40	MR4.5 for at least 2 years	Loss of MR5.0	42 months	47% at 24 months
HOVON <sup>164</sup>	Imatinib + cytarabine	15	MR4.5 for at least 2 years	Loss of MR4.5	36 months	33% at 24 months
A-STIM <sup>165</sup>	Imatinib ± interferon	80	MR5.0 for at least 2 years	Loss of MMR	31 months	64% at 24 months; 61% at 36 months
ISAV <sup>166</sup>	Imatinib	112	CMR for at least 18 months	Loss of MMR	22 months	52%
KIDS <sup>167</sup>	Imatinib ± interferon	90	MR4.5 for at least 2 years	Loss of MMR	27 months	62% at 12 months; 58.5% at 24 months
Stop 2G-TKI <sup>168</sup>	Dasatinib/Nilotinib (first-line or second-line)	52	MR4.5 for at least 24 months	Loss of MMR	12 months	61% at 12 months; 57% at 24 months
DADI <sup>169</sup>	Dasatinib (second-line)	63	MR4.0 for at least 12 months	Loss of MR4.0	20 months	49% at 6 months
ENESTFreedom <sup>170</sup>	Nilotinib (first-line)	190	MR4.5 for 12 months	Loss of MMR	12 months	52%
ENESTop <sup>171</sup>	Nilotinib (second-line)	126	MR4.5 for 12 months	Loss of MR4.0 or Loss of MMR	48 weeks	58%
EuroSKI <sup>172</sup>	Imatinib/Dasatinib/Nilotinib (first-line or second-line)	717	MR4.0 for at least one year	Loss of MMR	10 months	53%

**MR5.0:** 5-log reduction in *BCR ABL1* levels and undetectable minimal residual disease on QPCR with a sensitivity of  $\geq 4.5$ -log reduction;

**MR4.5:**  $\leq 0.0032\%$  *BCR-ABL1* IS or  $>4.5$ -log reduction of *BCR-ABL1* and undetectable minimal residual disease on QPCR with a sensitivity of  $\geq 4.5$ -log reduction;

**MR4.0:**  $<0.01\%$  *BCR-ABL1* IS;

**Major molecular response (MMR):**  $\leq 0.1\%$  *BCR-ABL1* IS;

**Complete molecular response (CMR):** undetectable *BCR-ABL1* by QPCR as determined by local laboratory.

### References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017;67:7-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28055103>.
2. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. *N Engl J Med* 1999;341:164-172. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10403855>.
3. Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. *Blood* 2009;114:2232-2235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19531657>.
4. Sawyers CL. Chronic myeloid leukemia. *N Engl J Med* 1999;340:1330-1340. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10219069>.
5. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc Natl Acad Sci U S A* 2006;103:2794-2799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16477019>.
6. Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *N Engl J Med* 2004;351:657-667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15306667>.
7. U.S. National Library of Medicine Key MEDLINE® Indicators Available at: [http://www.nlm.nih.gov/bsd/bsd\\_key.html](http://www.nlm.nih.gov/bsd/bsd_key.html).
8. Douet-Guilbert N, Morel F, Le Charpentier T, et al. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. *Anticancer Res* 2004;24:2535-2539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15330210>.
9. Seong DC, Kantarjian HM, Ro JY, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. *Blood* 1995;86:2343-2349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7662980>.
10. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. *Blood* 1998;91:3357-3365. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9558393>.
11. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. *Clin Cancer Res* 2003;9:160-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12538464>.
12. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood* 2006;108:28-37. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16522812>.
13. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2003;349:1423-1432. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14534335>.
14. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. *Leukemia* 2003;17:2474-2486. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14562124>.

15. Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. *Blood* 1995;86:3118-3122. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7579406>.
16. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. *Blood* 1998;92:3362-3367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9787174>.
17. Sokal J, Cox E, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. *Blood* 1984;63:789-799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6584184>.
18. Hasford J, Pffirmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. *J Natl Cancer Inst* 1998;90:850-858. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9625174>.
19. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. *Blood* 2011;118:686-692. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21536864>.
20. Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. *J Clin Oncol* 2011;29:3944-3945. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21900102>.
21. Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. *Blood* 2012;119:4524-4526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22431574>.
22. Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. *Cancer Sci* 2014;105:105-109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24450386>.
23. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016;127:2391-2405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27069254>.
24. Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. *Cancer* 2006;106:1306-1315. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16463391>.
25. O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. *Blood* 2002;100:1628-1633. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12176881>.
26. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. *Blood* 2003;101:3794-3800. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12560227>.
27. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. *Blood* 2004;103:451-455. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14512312>.
28. Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. *Cancer* 2010;116:2673-2681. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20499401>.

29. Fabarius A, Kalmanti L, Dietz CT, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. *Ann Hematol* 2015;94:2015-2024. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26385387>.

30. Bumm T, Muller C, Al-Ali H-K, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. *Blood* 2003;101:1941-1949. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12411298>.

31. Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. *Exp Hematol* 2003;31:702-707. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12901975>.

32. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. *Cancer* 2003;98:1905-1911. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14584073>.

33. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. *Leukemia* 2004;18:1340-1346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15190256>.

34. Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. *Cancer* 2007;110:1509-1519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17702093>.

35. Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly

diagnosed chronic myeloid leukemia in chronic phase. *Blood* 2007;110:2991-2995. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17625066>.

36. Karimata K, Masuko M, Ushiki T, et al. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. *Intern Med* 2011;50:481-485. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21372464>.

37. Navarro JT, Feliu E, Grau J, et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. *Am J Hematol* 2007;82:849-851. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17563075>.

38. Druker BJ. Chronic Myelogenous Leukemia In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology*. Vol. 2 (ed 8): Lippincott, Williams and Wilkins; 2007:2267-2304.

39. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2006;355:2408-2417. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17151364>.

40. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. *Blood* 2009;114:Abstract 1126. Available at: <http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/1126>.

41. Guilhot F, Druker B, Larson RA, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. *Haematologica* 2009;94:1669-1675. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19648168>.



# NCCN Guidelines Version 1.2018

## Chronic Myeloid Leukemia

42. Hughes T, Branford S, White D, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. *Blood* 2008;112:3965-3973. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18768781>.
43. Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. *J Clin Oncol* 2009;27:4754-4759. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19720924>.
44. Baccarani M, Druker BJ, Branford S, et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. *Int J Hematol* 2014;99:616-624. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24658916>.
45. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. *J Clin Oncol* 2014;32:415-423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24297946>.
46. Deininger MW, Kopecky KJ, Radich JP, et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. *Br J Haematol* 2014;164:223-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24383843>.
47. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. *J Clin Oncol* 2016;34:2333-2340. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27217448>.
48. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia. *Blood* 2012;120:3898-3905. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22915637>.
49. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia* 2016;30:1044-1054. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26837842>.
50. Brummendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. *Br J Haematol* 2015;168:69-81. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25196702>.
51. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2010;362:2260-2270. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20525995>.
52. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. *J Clin Oncol* 2007;25:3908-3914. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17761974>.
53. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. *Cancer* 2010;116:377-386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19924787>.
54. Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. *Cancer* 2016;122:1398-1407. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26998677>.

55. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. *Blood* 2009;114:261-263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19414863>.
56. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation* 2012;125:2128-2137. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22451584>.
57. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. *Leuk Res* 2012;36:e4-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21890201>.
58. Serpa M, Sanabani SS, Bendit I, et al. Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. *Clin Med Insights Oncol* 2010;4:155-162. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21234296>.
59. Santos FP, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. *Br J Haematol* 2010;150:303-312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20553275>.
60. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. *Am J Respir Crit Care Med* 2007;176:814-818. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17600277>.
61. Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. *Cancer* 2003;98:2483-2487. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14635084>.
62. Aleem A. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. *Hematol Oncol Stem Cell Ther* 2009;2:358-361. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20118061>.
63. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. *Leukemia* 2013;27:1511-1519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23417029>.
64. Berman E, Nicolaidis M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. *N Engl J Med* 2006;354:2006-2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16687713>.
65. Berman E, Girotra M, Cheng C, et al. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. *Leuk Res* 2013;37:790-794. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23473999>.
66. Aichberger KJ, Herndlhofer S, Scherthaner G-H, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. *Am J Hematol* 2011;86:533-539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21538470>.
67. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. *Am J Hematol* 2011;86:610-611. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21630307>.
68. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia* 2013;27:1310-1315. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23459450>.
69. Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. *Blood*

2011;117:e75-87. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20810928>.

70. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. *Cancer* 2004;100:2592-2597. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15197801>.

71. Quintas-Cardama A, De Souza Santos FP, Kantarjian H, et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. *Cancer* 2009;115:3935-3943. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19517473>.

72. Santos FP, Alvarado Y, Kantarjian H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. *Cancer* 2011;117:982-991. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20960502>.

73. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. *Blood* 2009;113:5401-5411. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19349618>.

74. Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. *J Clin Oncol* 2010;28:2381-2388. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20385986>.

75. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. *Blood* 2011;117:3733-3736. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21346253>.

76. Branford S, Yeung DT, Prime JA, et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. *Blood* 2012;119:4264-4271. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22431575>.

77. Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. *Curr Med Res Opin* 2010;26:2861-2869. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21062136>.

78. Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. *Curr Med Res Opin* 2012;28:213-219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22168217>.

79. Quintas-Cardama A, Cortes JE, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. *Clin Lymphoma Myeloma* 2008;8 Suppl 3:S82-88. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19254885>.

80. Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. *J Support Oncol* 2012;10:14-24. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22244674>.

81. Landstrom AP, Ketterling RP, Knudson RA, Tefferi A. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. *Leuk Lymphoma* 2006;47:2055-2061. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17071476>.

82. Muhlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment.

Genes Chromosomes Cancer 1998;21:90-100. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/9491319>.

83. Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009;114:4939-4943. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19797518>.

84. Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011;117:1245-1252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21381013>.

85. Hughes T, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-3765. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20679528>.

86. Akard LP, Cortes JE, Albitar M, et al. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the rationale and insight for gleevec high-dose therapy study. Arch Pathol Lab Med 2014;138:1186-1192. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24308645>.

87. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-1930. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16990771>.

88. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355-365. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19959086>.

89. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-3338. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18684859>.

90. Guerin A, Chen L, Dea K, et al. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin 2014;30:1345-1352. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24640967>.

91. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-238. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22067393>.

92. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-2102. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22446502>.

93. Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013;121:2739-2742. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23380743>.

94. Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011;118:4541-4546. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21803854>.

95. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic



myeloid leukemia with an imatinib-induced complete cytogenetic response. *Clin Cancer Res* 2007;13:6136-6143. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17947479>.

96. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. *J Clin Oncol* 2008;26:3358-3363. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18519952>.

97. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. *Blood* 2008;112:4437-4444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18716134>.

98. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon- $\alpha$  in newly diagnosed chronic myeloid leukemia. *J Clin Oncol* 2011;29:1634-1642. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21422420>.

99. Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? *J Clin Oncol* 2011;29:4260-4265. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21990394>.

100. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood* 2014;123:494-500. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24311723>.

101. Cervantes F, López-Garrido P, Montero MI, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. *Haematologica* 2010;95:1317-1324. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20220063>.

102. Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. *J Clin Oncol* 2011;29:1512-1516. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21422414>.

103. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. *Blood* 2004;104:3739-3745. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15315971>.

104. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. *Cancer Res* 2008;68:9809-9816. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19047160>.

105. Hegedus C, Ozvegy-Laczka C, Apati A, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. *Br J Pharmacol* 2009;158:1153-1164. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19785662>.

106. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. *Blood* 2007;109:3496-3499. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17192396>.

107. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. *Blood* 2008;111:4022-4028. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18256322>.

108. Bouchet S, Titier K, Moore N, et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. *Fundam Clin Pharmacol* 2013;27:690-697. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23113675>.

109. White DL, Radich J, Soverini S, et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomised to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose. *Haematologica* 2012;97:907-914. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22207690>.

110. Giannoudis A, Davies A, Lucas CM, et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. *Blood* 2008;112:3348-3354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18669873>.

111. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. *Clin Cancer Res* 2008;14:3881-3888. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18559609>.

112. Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. *Leukemia* 2009;23:1999-2006. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19710702>.

113. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. *Blood* 2006;108:697-704. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16597591>.

114. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. *Blood* 2003;102:276-283. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12623848>.

115. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front

cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. *J Clin Oncol* 2005;23:4100-4109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15867198>.

116. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). *Leukemia* 2006;20:1061-1106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16642048>.

117. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. *Clin Cancer Res* 2006;12:7374-7379. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17189410>.

118. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. *J Clin Oncol* 2008;26:4806-4813. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18645191>.

119. Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. *Haematologica* 2007;92:1238-1241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17768119>.

120. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. *Blood* 2008;112:53-55. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18403620>.

121. Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase



domain. *Haematologica* 2007;92:401-404. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17339191>.

122. Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. *Blood* 2008;112:4839-4842. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18818391>.

123. Muller MC, Cortes JE, Kim D-W, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. *Blood* 2009;114:4944-4953. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19779040>.

124. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *J Clin Oncol* 2009;27:4204-4210. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19652056>.

125. Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. *Blood* 2009;114:2168-2171. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19589924>.

126. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood* 2012;119:3403-3412. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22371878>.

127. Deininger MW, Cortes JE, Kim D-W, et al. Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia [abstract]. *J Clin Oncol* 2013;31(15\_suppl):Abstract 7001. Available at:  
[http://meeting.ascopubs.org/cgi/content/abstract/31/15\\_suppl/7001](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7001).

128. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. *Blood* 2004;104:2926-2932. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15256429>.

129. Wang L, Knight K, Lucas C, Clark R. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. *Haematologica* 2006;91:235-239. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16461309>.

130. Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. *J Clin Oncol* 2009;27:3659-3663. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19487383>.

131. Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? *Br J Haematol* 2009;145:373-375. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19344397>.

132. Press RD, Willis SG, Laudadio J, et al. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. *Blood* 2009;114:2598-2605. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19625707>.

133. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. *Blood* 2014;124:511-518. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24859364>.

134. Branford S, Yeung DT, Ross DM, et al. The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment

[abstract]. Blood 2014;124:Abstract 816. Available at:  
<http://www.bloodjournal.org/content/124/21/816.abstract>.

135. Hanfstein B, Shlyakhto V, Lauseker M, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014;28:1988-1992. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24798484>.

136. Iriyama N, Fujisawa S, Yoshida C, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Am J Hematol 2015;90:282-287. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25530131>.

137. Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014;38:10-20. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/24131888>.

138. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12393385>.

139. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102:2702-2704. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/14504074>.

140. Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-2160. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19060245>.

141. Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-560. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19117345>.

142. Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-4147. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19536906>.

143. Shah NP, Rousselot P, Schiffer CA, et al. Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results [abstract]. Blood 2014;124:Abstract 520. Available at:  
<http://www.bloodjournal.org/content/124/21/520.abstract>.

144. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-112. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22763385>.

145. Yeung DT, Osborn MP, White DL, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015;125:915-923. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/25519749>.

146. Brummendorf TH, Cortes JE, Khoury HJ, et al. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol 2016;172:97-110. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26537529>.

147. Nazha A, Kantarjian H, Jain P, et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major

cytogenetic response at 3 months. *Haematologica* 2013;98:1686-1688. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23812943>.

148. Cortes JE, Khoury HJ, Kantarjian HM, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. *Am J Hematol* 2016;91:1206-1214. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27531525>.

149. Cortes JE, Pinilla-Ibarz J, Le Coutre PD, et al. 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. *J Clin Oncol* 2016;34:7013. Available at: <http://meetinglibrary.asco.org/content/163683-176>.

150. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias. *New England Journal of Medicine* 2013;369:1783-1796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24180494>.

151. Full prescribing Information for ponatinib. 2014. Available at: <http://www.iclusiq.com/wp-content/uploads/2014/08/July-2014-Iclusiq-Prescribing-Information.pdf>.

152. Knickerbocker R, Dorer DJ, Haluska FG, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients [abstract]. *Blood* 2014;124:Abstract 4546. Available at: <http://www.bloodjournal.org/content/124/21/4546.abstract>.

153. Hochhaus A, Pinilla-Ibarz J, Kim D-W, et al. Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias [abstract]. *J Clin Oncol* 2014;32 (15\_suppl):Abstract 7084. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/32/15\\_suppl/7084](http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7084).

154. Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. *Blood* 2012;120:2573-2580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22896000>.

155. Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. *Am J Hematol* 2013;88:350-354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23468307>.

156. Cortes JE, Nicolini FE, Wetzler M, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. *Clin Lymphoma Myeloma Leuk* 2013;13:584-591. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23787123>.

157. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood* 2014;123:2317-2324. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24569263>.

158. Muller MC, Baccarani M, Deininger MW, et al. Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts). *J Clin Oncol* 2016;34:7053. Available at: <http://meetinglibrary.asco.org/content/162710-176>.

159. Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. *Blood* 2009;114:4361-4368. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19729517>.

160. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol* 2010;10:29-35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20965785>.

161. Etienne G, Rea D, Guilhot J, et al. Long-term follow-up of the French 1 stop imatinib study (STIM1) in chronic myeloid leukemia patients [abstract]. *Blood* 2015;126:Abstract 345. Available at: <http://www.bloodjournal.org/content/126/23/345.abstract>.

162. Nicolini FE, Noël M-P, Escoffre M, et al. Preliminary report of the STIM2 study: A multicenter stop imatinib trial for chronic phase chronic myeloid leukemia *de novo* patients on imatinib [abstract]. Blood 2013;122:Abstract 654. Available at:

<http://www.bloodjournal.org/content/122/21/654.abstract>.

163. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-522. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23704092>.

164. Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 2013;49:3242-3246. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23876833>.

165. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424-430. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24323036>.

166. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 2015;90:910-914. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26178642>.

167. Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 2016;101:717-723. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26888022>.

168. Rea D, Nicolini FE, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable bcr-abl transcripts: Interim analysis of the stop 2G-TKI study with a minimum follow-up of 12 months – on behalf of the French CML Group Filmc [abstract]. Blood 2014;124:Abstract 811. Available at:

<http://www.bloodjournal.org/content/124/21/811.abstract>.

169. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015;2:e528-535. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26686407>.

170. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. J Clin Oncol 2016;34 (Suppl):Abstract 7001. Available at:

<http://meetinglibrary.asco.org/content/166320-176>.

171. Hughes TP, Boquimpani C, Kim D-W, et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study. J Clin Oncol 2016;34 (Suppl):Abstract 7054. Available at:

<http://meetinglibrary.asco.org/content/164769-176>.

172. Richter J, Mahon F, Guilhot J, et al. Stopping tyrosine kinase inhibitors in a very large cohort of european chronic myeloid leukemia patients: Results of the EURO-SKI trial. Haematologica 2016;101 (Suppl 1):Abstract S145. Available at:

<http://www.haematologica.org/content/101/s1/1.abstract>.

173. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016;128:17-23. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27013442>.

174. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated

phase chronic myeloid leukemia: results of a phase 2 study. *Blood* 2002;99:1928-1937. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11877262>.

175. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood* 2002;99:3547-3553. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11986206>.

176. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood* 2002;99:3530-3539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11986204>.

177. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. *Haematologica* 2008;93:1792-1796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18838477>.

178. Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. *Haematologica* 2009;94:205-212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19144656>.

179. Rea D, Etienne G, Nicolini F, et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. *Leukemia* 2012;26:2254-2259. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22460758>.

180. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. *Blood* 2009;113:6322-6329. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19369231>.

181. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. *Cancer* 2010;116:3852-3861. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20564086>.

182. le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. *Leukemia* 2012;26:1189-1194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22076466>.

183. Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. *Leukemia* 2012;26:959-962. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22157807>.

184. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. *Am J Hematol* 2015;90:755-768. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26040495>.

185. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial [abstract]. *Blood* 2014;124:Abstract 3135. Available at: <http://www.bloodjournal.org/content/124/21/3135.abstract>.

186. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. *Cancer* 2007;109:899-906. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17236224>.

187. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. *Leuk Lymphoma*



2007;48:283-289. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17325887>.

188. Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.

Cancer 2007;109:1543-1549. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17340589>.

189. Deau B, Nicolini FE, Guilhot J, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res 2011;35:777-782. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21145590>.

190. Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 2014;89:282-287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24779033>.

191. Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 2014;120:373-380. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24151050>.

192. Khoury HJ, Cortes J, Bacarani M, et al. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leuk Lymphoma 2015;56:120-127. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24650054>.

193. Velev N, Cortes J, Champlin R, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 2010;116:3631-3637. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20564073>.

194. Jabbour E, Cortes J, Santos FP, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011;117:3641-3647.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21156844>.

195. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011;118:5697-5700. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21926354>.

196. Nair AP, Barnett MJ, Broady RC, et al. Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronic myeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors. Biol Blood Marrow Transplant 2015;21:1437-1444. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25865648>.

197. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9521984>.

198. Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-346. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11286947>.

199. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-2976. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15998838>.

200. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia





in first chronic phase. Blood 2003;101:441-445. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12393604>.

201. Faber E, Koza V, Vitek A, et al. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 2007;54:443-446. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17688375>.

202. Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007;110:3456-3462. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17652620>.

203. Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012;119:4083-4090. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22408257>.

204. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006;91:452-459. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16585011>.

205. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782-1789. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17062727>.

206. Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-

related toxicity. Cancer 2007;110:340-344. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17559140>.

207. Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 2009;23:190-194. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/18596746>.

208. Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res 2010;34:143-147. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19481800>.

209. Lee SE, Choi SY, Kim SH, et al. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Hematology 2014;19:63-72. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23684143>.

210. Piekarska A, Gil L, Prejzner W, et al. Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. Ann Hematol 2015;94:1891-1897. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26220759>.

211. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-1092. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/9798583>.

212. Pavlu J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation



in chronic myeloid leukemia in chronic phase. *Blood* 2010;115:4018-4020. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20304808>.

213. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. *Bone Marrow Transplant* 1996;17 Suppl 3:S5-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8769690>.

214. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). *Haematologica* 2006;91:513-521. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16533723>.

215. Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. *J Clin Oncol* 2010;28:1888-1895. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20212247>.

216. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. *Blood* 2010;115:1880-1885. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19965667>.

217. Boehm A, Walcherberger B, Sperr WR, et al. Improved outcome in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: A single center experience. *Biol Blood Marrow Transplant* 2011 17:133-140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20601032>.

218. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. *Bone Marrow Transplant* 2012;47:810-816. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21986636>.

219. Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. *Blood* 2009;113:5058-5063. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19282457>.

220. Rajappa S, Uppin SG, Raghunadharao D, et al. Isolated central nervous system blast crisis in chronic myeloid leukemia. *Hematol Oncol* 2004;22:179-181. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15995975>.

221. Kim HJ, Jung CW, Kim K, et al. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. *J Clin Oncol* 2006;24:4028-4029. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16921058>.

222. Altintas A, Cil T, Kilinc I, et al. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. *J Neurooncol* 2007;84:103-105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17318411>.

223. Aftimos P, Nasr F. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature. *Leuk Res* 2009;33:e178-180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19446330>.

224. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. *Blood* 2008;112:1005-1012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18477770>.

225. Delage R, Soiffer R, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. *Blood* 1991;78:2759-2767. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1824268>.

226. Roth M, Antin J, Ash R, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. *Blood* 1992;79:276-282. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1728316>.

227. van Rhee F, Lin F, Cross NC, et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. *Bone Marrow Transplant* 1994;14:609-612. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7858536>.

228. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. *Blood* 1995;85:2632-2638. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7727789>.

229. Costello RT, Kirk J, Gabert J. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. *Leuk Lymphoma* 1996;20:239-243. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8624462>.

230. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. *Bone Marrow Transplant* 1996;17:643-647. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8722369>.

231. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood* 2001;97:1560-1565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11238091>.

232. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18

months or more after transplantation. *Blood* 2001;98:1701-1707. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11535500>.

233. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. *Blood* 1995;86:2041-2050. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7655033>.

234. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood* 2000;96:2712-2716. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11023502>.

235. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. *Cancer Control* 2002;9:123-137. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11965233>.

236. Michallet AS, Nicolini F, Furst S, et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). *Bone Marrow Transplant* 2005;35:601-608. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15756285>.

237. Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. *Haematologica* 2006;91:663-666. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16627251>.

238. Chalandon Y, Passweg JR, Guglielmi C, et al. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. *Haematologica* 2014;99:1492-1498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24997146>.



239. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. *Blood* 2000;95:67-71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10607686>.

240. Shimoni A, Gajewski JA, Donato M, et al. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. *Biol Blood Marrow Transplant* 2001;7:568-575. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11760089>.

241. Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. *Leuk Lymphoma* 2003;44:23-28. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12691139>.

242. Posthuma EFM, Marijt EWF, Barge RMY, et al. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. *Biol Blood Marrow Transplant* 2004;10:204-212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14993886>.

243. Simula MP, Markt S, Fozza C, et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. *Leukemia* 2007;21:943-948. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17361226>.

244. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood* 2002;100:1590-1595. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12176876>.

245. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for

chronic myeloid leukemia. *Leukemia* 2003;17:1707-1712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12970768>.

246. Anderlini P, Sheth S, Hicks K, et al. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. *Biol Blood Marrow Transplant* 2004;10:883-884. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15570257>.

247. DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. *Clin Cancer Res* 2004;10:5065-5071. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297408>.

248. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. *J Clin Oncol* 2005;23:7583-7593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16234522>.

249. Palandri F, Amabile M, Rosti G, et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. *Bone Marrow Transplant* 2007;39:189-191. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17211436>.

250. Conchon M, Sanabani SS, Bendit I, et al. The use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation. *J Transplant* 2009;2009:357093-357093. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20107580>.

251. Wright MP, Shepherd JD, Barnett MJ, et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*

2010;16:639-646. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20005967>.

252. Atallah E, Kantarjian H, De Lima M, et al. The role of dasatinib in patients with philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT) [abstract]. Blood 2006;108:Abstract 4520.

Available at:

<http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/4520>.

253. O'Connor LM, Langabeer S, McCann SR, Conneally E. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. Bone Marrow Transplant 2008;42:833-835. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18711344>.

254. Breccia M, Cannella L, Stefanizzi C, et al. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant 2009;44:331-332. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19219075>.

255. Klyuchnikov E, Schafhausen P, Kroger N, et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009;122:6-10. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19602874>.

256. Garland P, Dazzi F, Marin D. Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant 2010;45:395-396. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19561650>.

257. Reinwald M, Schleyer E, Kiewe P, et al. Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation. Biomed Res

Int 2014;2014:637059. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25025064>.

258. Shimoni A, Volchek Y, Koren-Michowitz M, et al. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2015;121:863-871. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25387866>.

259. Carpenter PA, Snyder DS, Flowers MED, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791-2793. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17119111>.

260. Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007;110:4614-4617. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17881635>.

261. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1009-1015. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16205732>.

262. Shanavas M, Messner HA, Kamel-Reid S, et al. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 2014;14:87-92. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24252361>.

263. Zeidner JF, Zahurak M, Rosner GL, et al. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma



2015;56:128-134. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24712979>.

264. Egan DN, Beppu L, Radich JP. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation. *Biol Blood Marrow Transplant* 2015;21:184-189. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25300870>.

265. Oshima K, Kanda Y, Yamashita T, et al. Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2008;14:1100-1107.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18804039>.

266. Fuchs M, Reinhofer M, Ragoschke-Schumm A, et al. Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. *BMC Blood Disord* 2012;12:9. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22871019>.

267. Ocheni S, Iwanski GB, Schafhausen P, et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. *Leuk Lymphoma* 2009;50:551-558. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19373652>.

268. Nishimoto M, Nakamae H, Koh KR, et al. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia. *Acta Haematol* 2013;130:111-114. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23548721>.

269. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. *Leukemia* 2015;29:1336-1343.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25783795>.

270. Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. *Br J Haematol* 2007;137:374-375. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17408403>.

271. Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. *Leuk Res* 2008;32:519-520. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17804066>.

272. Oweini H, Otrrock ZK, Mahfouz RAR, Bazarbachi A. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. *Arch Gynecol Obstet* 2010. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20473616>.

273. Ghalaut VS, Prakash G, Bansal P, et al. Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report. *J Oncol Pharm Pract* 2014;20:243-248. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23966360>.

274. Alizadeh H, Jaafar H, Rajnics P, et al. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. *Leuk Res* 2015;39:47-51.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25455655>.

275. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. *Blood* 2008;111:5505-5508. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18322153>.

276. Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. *Am J Hematol* 2015;90:1111-1115. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26348106>.

277. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. *J Clin Oncol* 2006;24:1204-1208. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16446320>.

278. Kuwabara A, Babb A, Ibrahim A, et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. *Blood* 2010;116:1014-1016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20705771>.

279. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. *J Perinatol* 2007;27:241-243. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17377606>.

280. Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. *Arch Gynecol Obstet* 2009;280:169-175. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19083009>.

281. Ali R, Ozkalemkas F, Ozkocaman V, et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. *Jpn J Clin Oncol* 2004;34:215-217. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15121759>.

282. Koh LP, Kanagalingam D. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. *Int J Hematol* 2006;84:459-462. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17189230>.

283. Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. *Ann Hematol* 2015;94 Suppl 2:S167-176. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25814083>.

284. James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. *Obstet Gynecol Surv* 2008;63:49-57. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18081940>.

285. Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy--how safe are they? *Curr Opin Obstet Gynecol* 2007;19:573-577. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18007136>.

286. Haggstrom J, Adriansson M, Hybbinette T, et al. Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum. *Eur J Haematol* 1996;57:101-102. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8698119>.

287. Kuroiwa M, Gondo H, Ashida K, et al. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy. *Am J Hematol* 1998;59:101-102. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9723590>.

288. Lipton JH, Derzko CM, Curtis J. Alpha-interferon and pregnancy in a patient with CML. *Hematol Oncol* 1996;14:119-122. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9119356>.

289. Al Bahar S, Pandita R, Nath SV. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. *Int J Gynaecol Obstet* 2004;85:281-282. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15145269>.

290. Baykal C, Zengin N, Coskun F, et al. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report. *Eur J Gynaecol Oncol* 2000;21:89-90. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10726630>.

291. Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. *Leukemia* 2001;15:1309-1311. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11480579>.

292. Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M. Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. *Leukemia* 2002;16:1202-1203. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12040456>.

293. de la Fuente J, Baruchel A, Biondi A, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18

years. Br J Haematol 2014;167:33-47. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/24976289>.

294. Hijjiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. *Pediatr Clin North Am* 2015;62:107-119. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25435115>.

295. Hijjiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. *Blood* 2016;127:392-399. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/26511135>.

296. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. *Blood* 2004;104:2655-2660. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/15231574>.

297. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. *J Clin Oncol* 2011;29:2827-2832. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/21670449>.

298. Millot F, Guilhot J, Baruchel A, et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. *Blood* 2014;124:2408-2410. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25170123>.

299. Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2011;57:56-62. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/21465636>.

300. Giona F, Putti MC, Micalizzi C, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid

leukaemia in chronic phase: the Italian experience. Br J Haematol 2015;170:398-407. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25891192>.

301. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. *Leukemia* 2006;20:187-192. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/16341042>.

302. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. *J Clin Oncol* 2011;29:839-844. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21263099>.

303. Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. *J Clin Oncol* 2013;31:2460-2468. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23715577>.

304. Wayne AS, Macedo CR, Szczudlo T, Woodman RC. Nilotinib treatment in pediatric patients (pts) with Philadelphia chromosome-positive (Ph+) leukemia refractory to prior tyrosine kinase inhibitor (TKI) therapy: results from nilotinib compassionate use program [abstract]. *Blood* 2015;112:Abstract 4264. Available at:  
<http://www.bloodjournal.org/content/112/11/4264.abstract>.

305. Nickel RS, Daves M, Keller F. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. *Pediatr Blood Cancer* 2015;62:2050-2051. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25939962>.

306. Gurrea Salas D, Glauche I, Tauer JT, et al. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? *Ann Hematol* 2015;94:1363-1371. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25894600>.





307. Millot F, Claviez A, Leverger G, et al. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. *Pediatr Blood Cancer* 2014;61:355-357. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24106110>.

308. Mariani S, Giona F, Basciani S, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. *Lancet* 2008;372:111-112. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18620939>.

309. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. *Int J Hematol* 2009;89:251-252. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19152100>.

310. Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. *Haematologica* 2009;94:1177-1179. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19546438>.

311. Hobernicht SL, Schweiger B, Zeitler P, et al. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. *Pediatr Blood Cancer* 2011;56:671-673. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21298759>.

312. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. *J Pediatr* 2011;159:676-681. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21592517>.

313. Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. *Pediatr Blood Cancer* 2012;59:481-484. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22052850>.

314. Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous

leukemia. *Pediatr Blood Cancer* 2012;59:840-845. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22378641>.

315. Narayanan KR, Bansal D, Walia R, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. *Pediatr Blood Cancer* 2013;60:1148-1153. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23322583>.

316. Samis J, Lee P, Zimmerman D, et al. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia. *Pediatr Blood Cancer* 2016;63:1332-1338. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27100618>.

317. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. *Hematology Am Soc Hematol Educ Program* 2010;2010:368-376. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21239821>.

318. de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. *Blood* 2013;122:227-238. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23719297>.

319. de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. *Haematologica* 2011;96:307-314. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20971824>.

320. Luthy KE, Tiedeman ME, Beckstrand RL, Mills DA. Safety of live-virus vaccines for children with immune deficiency. *J Am Acad Nurse Pract* 2006;18:494-503. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16999715>.